[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 110
1. Matsumoto S, Takahashi K, Iwakawa R, Matsuno Y, Nakanishi Y, Kohno T, Shimizu E, Yokota J: Frequent EGFR mutations in brain metastases of lung adenocarcinoma. Int J Cancer; 2006 Sep 15;119(6):1491-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent EGFR mutations in brain metastases of lung adenocarcinoma.
  • Lung adenocarcinomas often metastasize to the brain, and the prognosis of patients with brain metastases is still very poor.
  • The epidermal growth factor receptor (EGFR) gene is mutated in a considerable fraction of primary lung adenocarcinomas, in particular those with drastic response to EGFR tyrosine kinase inhibitors.
  • The present study was designed to elucidate the prevalence of EGFR mutations in brain metastases and the timing of their occurrence during cancer progression.
  • EGFR mutations were detected in 12 of 19 metastatic lung adenocarcinomas to the brain (63%).
  • This frequency was higher than those in previous studies for EGFR mutations at various stages of lung adenocarcinoma in East Asia, including Japan (i.e., 20-55%).
  • In 6 cases with EGFR mutations, the corresponding primary lung tumors were also examined for the mutations, and in all of them, the same types of EGFR mutations were detected also in the primary tumors.
  • In 2 of them, second metastatic brain tumors in addition to the first ones were also available for analysis, and the same types of EGFR mutations were detected in both the first and second ones in both cases.
  • These results indicate that EGFR mutations are present frequently in brain metastases and occur preceding brain metastasis.
  • These findings will be highly informative for treatment of metastatic lung adenocarcinoma to the brain.
  • [MeSH-major] Adenocarcinoma / genetics. Brain Neoplasms / genetics. Lung Neoplasms / genetics. Mutation. Receptor, Epidermal Growth Factor / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Cancer. 2007 Apr 15;120(8):1828-31; author reply 1832-3 [17236198.001]
  • (PMID = 16642476.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


2. McDonald JM, Pelloski CE, Ledoux A, Sun M, Raso G, Komaki R, Wistuba II, Bekele BN, Aldape K: Elevated phospho-S6 expression is associated with metastasis in adenocarcinoma of the lung. Clin Cancer Res; 2008 Dec 1;14(23):7832-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated phospho-S6 expression is associated with metastasis in adenocarcinoma of the lung.
  • PURPOSE: The primary objective of this study was to determine whether markers of differentiation and activation of the Akt pathway are associated with metastasis in adenocarcinoma of the lung.
  • EXPERIMENTAL DESIGN: Paired primary and metastatic tumor samples were obtained from 41 patients who had undergone resection of both primary lung adenocarcinoma and brain metastatic lesions.
  • Biomarkers that showed relative discordance in expression between the matched pairs were then assessed in a cohort of 77 primary lung adenocarcinomas.
  • Validation was done in an independent cohort of 82 primary lung adenocarcinomas.
  • In contrast, p-S6 overexpression was significantly associated with metastatic tumors (20 of 21 discordant pairs).
  • The expression of E-cadherin, p-S6, and TTF-1 was evaluated in 77 primary lung adenocarcinomas, in which high p-S6 expression was associated with shorter time to metastasis.
  • CONCLUSIONS: The biomarker p-S6 is overexpressed in metastatic tumors.
  • In primary tumors, higher p-S6 expression is associated with shorter metastatic-free survival.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2700-9 [10561344.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):710-7 [16467080.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):1122-8 [11221842.001]
  • [Cites] Eur Respir J. 2001 Oct;18(4):705-19 [11716177.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1216-24 [12128123.001]
  • [Cites] Cell. 2002 Oct 4;111(1):9-12 [12372295.001]
  • [Cites] Arch Pathol Lab Med. 2003 Feb;127(2):193-5 [12562233.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Feb;4(2):117-26 [12563289.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1070-6 [12631609.001]
  • [Cites] Respir Res. 2002;3:27 [12537604.001]
  • [Cites] Hum Pathol. 2003 Jun;34(6):597-604 [12827614.001]
  • [Cites] J Korean Med Sci. 2003 Aug;18(4):494-500 [12923324.001]
  • [Cites] Hum Pathol. 2004 Jan;35(1):3-7 [14745718.001]
  • [Cites] Mod Pathol. 2004 Apr;17(4):430-9 [14739904.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3935-41 [16818690.001]
  • [Cites] Virchows Arch. 2007 Mar;450(3):321-8 [17265080.001]
  • [Cites] Cancer. 2007 Jun 1;109(11):2257-67 [17440983.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6325-32 [17616691.001]
  • [Cites] Nat Rev Cancer. 2004 May;4(5):335-48 [15122205.001]
  • [Cites] Cancer Lett. 2004 Oct 28;214(2):157-64 [15363541.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6865-71 [15501963.001]
  • [Cites] Chest. 1992 Apr;101(4):1013-8 [1313349.001]
  • [Cites] BMJ. 1992 Feb 29;304(6826):541-3 [1313719.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • [Cites] Am J Respir Crit Care Med. 2004 Nov 15;170(10):1088-94 [15317667.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1530-7 [15735128.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 2001;65:101-27 [11008486.001]
  • (PMID = 19047111.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA070907-040007; United States / NCI NIH HHS / CA / P50 CA070907; United States / NCI NIH HHS / CA / P50 CA070907-040007; United States / NCI NIH HHS / CA / P50CA70907
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / DNA-Binding Proteins; 0 / Ribosomal Proteins; 0 / TTF1 protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  • [Other-IDs] NLM/ NIHMS83486; NLM/ PMC2614348
  •  go-up   go-down


3. Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, Abbruzzese JL: Metastatic patterns in adenocarcinoma. Cancer; 2006 Apr 1;106(7):1624-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic patterns in adenocarcinoma.
  • BACKGROUND: Unique metastatic patterns cited in the literature often arise from anecdotal clinical observations and autopsy reports.
  • The authors analyzed clinical data from a large number of patients with histologically confirmed, distant-stage adenocarcinoma to evaluate metastatic patterns.
  • METHODS: Tumor registry data were collected between 1994-1996 on 11 primary tumor sites and 15 metastatic sites from 4399 patients.
  • The primary and metastatic sites were cross-tabulated in various ways to identify patterns, and the authors developed algorithms by using multinomial logistic regression analysis to predict the locations of primary tumors based on metastatic patterns.
  • RESULTS: Three primary tumors had single, dominant metastatic sites: ovary to abdominal cavity (91%), prostate to bone (90%), and pancreas to liver (85%).
  • The liver was the dominant metastatic site for gastrointestinal (GI) primary tumors (71% of patients), whereas bone and lung metastases were noted most frequently in non-GI primary tumors (43% and 29%, respectively).
  • A single organ was the dominant source of metastases in 7 sites: axillary lymph node from the breast (97%), intestinal lymph node from the colon (84%), thoracic lymph node from the lung (66%), brain from the lung (64%), mediastinal lymph node from the lung (62%), supraclavicular lymph node from the breast (51%), and adrenal gland from the lung (51%).
  • [MeSH-major] Adenocarcinoma / secondary. Algorithms. Neoplasm Metastasis. Registries / statistics & numerical data

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16518827.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Arabi H, Shah M, Saleh H: Aspiration biopsy cytomorphology of primary pulmonary germ cell tumor metastatic to the brain. Diagn Cytopathol; 2009 Oct;37(10):715-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aspiration biopsy cytomorphology of primary pulmonary germ cell tumor metastatic to the brain.
  • Extragonadal germ cell tumors are uncommon and such tumors originating from the lung parenchyma are extremely rare.
  • Her workup revealed two enhancing brain lesions and large lung mass involving the left lower lobe.
  • Fine-needle aspiration (FNA) of the lung followed by craniotomy was performed and the patient was initially diagnosed with lung adenocarcinoma metastatic to the brain based on the cytomorphology of the lung FNA and histology of the brain mass.
  • However, retrospective investigation revealed markedly elevated alpha fetoprotein (AFP) of which the cytopathologist was unaware at the time of diagnosis.
  • A review of the cytology and surgical specimen slides, as well as immunohistochemistry (IHC) on the brain tumor and FNA cell block were preformed.
  • On the basis of the slides review, clinical findings, and immunostaining results, a diagnosis of primary pulmonary mixed germ cell tumor, containing choriocarcinoma and yolk sac elements, with brain metastases, was retrospectively made.
  • [MeSH-major] Brain Neoplasms / secondary. Lung Neoplasms / pathology. Neoplasms, Germ Cell and Embryonal / secondary
  • [MeSH-minor] Adenocarcinoma / pathology. Aged. Biopsy, Fine-Needle. Diagnostic Errors. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19373916.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


5. Lee HY, Lee KS, Kim BT, Cho YS, Lee EJ, Yi CA, Chung MJ, Kim TS, Kwon OJ, Kim H: Diagnostic efficacy of PET/CT plus brain MR imaging for detection of extrathoracic metastases in patients with lung adenocarcinoma. J Korean Med Sci; 2009 Dec;24(6):1132-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic efficacy of PET/CT plus brain MR imaging for detection of extrathoracic metastases in patients with lung adenocarcinoma.
  • We aimed to evaluate prospectively the efficacy of positron emission tomography (PET)/computed tomography (CT) plus brain magnetic resonance imaging (MRI) for detecting extrathoracic metastases in lung adenocarcinoma.
  • Metastatic evaluations were feasible for 442 consecutive patients (M:F=238:204; mean age, 54 yr) with a lung adenocarcinoma who underwent PET/CT (CT, without IV contrast medium injection) plus contrast-enhanced brain MRI.
  • The presence of metastases in the brain was evaluated by assessing brain MRI or PET/CT, and in other organs by PET/CT.
  • Diagnostic efficacies for metastasis detection with PET/CT plus brain MRI and with PET/CT only were calculated on a per-patient basis and compared from each other.
  • Of 442 patients, 88 (20%, including 50 [11.3%] with brain metastasis) had metastasis.
  • Regarding sensitivity of overall extrathoracic metastasis detection, a significant difference was found between PET/CT and PET/CT plus brain MRI (68% vs. 84%; P=0.03).
  • As for brain metastasis detection sensitivity, brain MRI was significantly higher than PET/CT (88% vs. 24%; P<0.001).
  • By adding MRI to PET/CT, brain metastases were detected in additional 32 (7% of 442 patients) patients.
  • In lung adenocarcinoma patients, significant increase in sensitivity can be achieved for detecting extrathoracic metastases by adding dedicated brain MRI to PET/CT and thus enhancing brain metastasis detection.
  • [MeSH-major] Adenocarcinoma. Carcinoma, Non-Small-Cell Lung. Lung Neoplasms. Neoplasm Metastasis. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 2003 Jan;123(1 Suppl):137S-146S [12527573.001]
  • [Cites] Lung Cancer. 2002 Jul;37(1):87-94 [12057872.001]
  • [Cites] Am Rev Respir Dis. 1979 Nov;120(5):1025-9 [228572.001]
  • [Cites] Radiology. 1983 Sep;148(3):839-43 [6878708.001]
  • [Cites] Chest. 1984 Dec;86(6):850-3 [6094117.001]
  • [Cites] J Clin Oncol. 1988 Sep;6(9):1474-80 [3047337.001]
  • [Cites] AJNR Am J Neuroradiol. 1991 Mar-Apr;12(2):293-300 [1902031.001]
  • [Cites] CA Cancer J Clin. 1992 Jan-Feb;42(1):19-38 [1728335.001]
  • [Cites] Thorax. 1994 Jan;49(1):14-9 [8153934.001]
  • [Cites] Am J Respir Crit Care Med. 1995 Jul;152(1):225-30 [7599828.001]
  • [Cites] Am J Respir Crit Care Med. 1997 Jul;156(1):320-32 [9230769.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Feb 1;43(3):505-9 [10078629.001]
  • [Cites] Chest. 1999 Mar;115(3):714-9 [10084481.001]
  • [Cites] Radiology. 1999 Sep;212(3):803-9 [10478250.001]
  • [Cites] Radiology. 2005 Sep;236(3):1011-9 [16014441.001]
  • [Cites] Radiology. 2007 Mar;242(3):882-8 [17229875.001]
  • [Cites] Cancer. 2007 Mar 15;109(6):1068-77 [17311309.001]
  • [Cites] Eur Respir J. 2007 May;29(5):995-1002 [17331966.001]
  • [Cites] J Magn Reson Imaging. 2007 Sep;26(3):498-509 [17729341.001]
  • [Cites] Chest. 2007 Sep;132(3 Suppl):178S-201S [17873168.001]
  • [Cites] J Thorac Oncol. 2008 Feb;3(2):140-4 [18303434.001]
  • [Cites] Radiology. 2008 Aug;248(2):632-42 [18552311.001]
  • [Cites] Ann Thorac Surg. 2001 Feb;71(2):425-33; discussion 433-4 [11235682.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1344-9 [11230477.001]
  • [Cites] CA Cancer J Clin. 2002 Jan-Feb;52(1):23-47 [11814064.001]
  • [Cites] Cancer. 1974 Feb;33(2):492-6 [4812766.001]
  • (PMID = 19949671.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2775863
  • [Keywords] NOTNLM ; Brain / Lung Neoplasms / Magnetic Resonance Imaging / Neoplasm Metastasis / Neoplasm Staging / PET/CT Scan
  •  go-up   go-down


6. Wu C, Li YL, Wang ZM, Li Z, Zhang TX, Wei Z: Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain. Lung Cancer; 2007 Sep;57(3):359-64
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain.
  • BACKGROUND: Lung cancer is the leading cause of cancer deaths in most countries.
  • In patients with metastases, such as the brain, the 1-year survival is 10% and most of these patients die in 1-3 months.
  • Data from large phase II trials of non-small cell lung cancer (NSCLC) suggested that the histologic subtype of adenocarcinoma may be a prognostic factor for patients treated with gefitinib.
  • To evaluate the efficacy of gefitinib in palliative therapy for advanced patients with adenocarcinoma and brain metastases, we conducted a phase II study.
  • PATIENTS AND METHODS: Eligible patients had histologically confirmed adenocarcinoma and brain metastases confirmed with radiological studies.
  • CONCLUSIONS: Our data suggest that gefitinib has promising activity in palliative therapy for patients with advanced lung adenocarcinoma and brain metastasis.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Brain Neoplasms / secondary. Lung Neoplasms / drug therapy. Palliative Care. Quinazolines / therapeutic use

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17434236.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


7. Lee DH, Han JY, Lee HG, Lee JJ, Lee EK, Kim HY, Kim HK, Hong EK, Lee JS: Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers. Clin Cancer Res; 2005 Apr 15;11(8):3032-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers.
  • PURPOSE: A subset of patients with adenocarcinoma of the lung who had never smoked cigarettes showed excellent tumor responses to gefitinib therapy.
  • EXPERIMENTAL DESIGN: Eligible patients had no smoking history, stage IIIB or IV adenocarcinoma, Eastern Cooperative Oncology Group performance status 0 to 2, and adequate organ functions.
  • Of 10 patients with evaluable brain metastases, 7 had objective responses in both intracranial and extracranial lesions, 1 had stable disease in the brain and dramatic response in the extracranial lesions, and 2 had progressive disease in both sites.
  • CONCLUSIONS: Gefitinib showed very dramatic antitumor activity, even in the brain, with unprecedented survival outcome in never-smoker adenocarcinoma patients.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use
  • [MeSH-minor] Adult. Aged. Brain Neoplasms / prevention & control. Brain Neoplasms / secondary. Disease Progression. Exanthema / chemically induced. Female. Follow-Up Studies. Humans. Male. Middle Aged. Skin Diseases / chemically induced. Smoking. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15837758.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


8. Granata A, Figura M, Gulisano S, Romeo G, Sicurezza E, Failla A, Scuderi R: [Central diabetes insipidus as a first manifestation of lung adenocarcinoma]. Clin Ter; 2007 Nov-Dec;158(6):519-22
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Central diabetes insipidus as a first manifestation of lung adenocarcinoma].
  • [Transliterated title] Diabete insipido centrale come prima manifestazione di adenocarcinoma polmonare.
  • The pituitary gland and infundibulum can be involved in a variety of medical conditions, including infiltrative diseases, fungal infections, tuberculosis, primary and metastatic tumors.
  • Computed tomography (CT) scan of the brain showed a mass located in the sella turcica and suprasellar region.
  • Bronchoscopy and biopsy demonstrated a pulmonary adenocarcinoma.
  • Thus, we made a diagnosis of lung cancer with local and pituitary metastases.
  • In conclusion, in patients presenting with sudden onset of diabetes insipidus pituitary metastases should be taken in account in differential diagnosis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Diabetes Insipidus / etiology. Lung Neoplasms / diagnosis. Pituitary Neoplasms / complications. Pituitary Neoplasms / secondary
  • [MeSH-minor] Biopsy. Bronchoscopy. Diagnosis, Differential. Humans. Lymphatic Metastasis. Magnetic Resonance Imaging. Male. Middle Aged. Polyuria / etiology. Thirst. Tomography, X-Ray Computed


9. Kong A, Koukourou A, Boyd M, Crowe G: Metastatic adenocarcinoma mimicking 'target sign' of cerebral tuberculosis. J Clin Neurosci; 2006 Nov;13(9):955-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adenocarcinoma mimicking 'target sign' of cerebral tuberculosis.
  • The 'target sign' of intracerebral tuberculomata was first described in 1979 and reported to be pathognomic for this diagnosis in 1988.
  • Subsequent histopathology demonstrated metastatic papillary adenocarcinoma and immunohistochemical studies revealed the origin to be that of primary lung carcinoma.
  • In summary, the 'target sign' is a non-specific radiologic finding but most commonly indicates cerebral tuberculoma or metastatic adenocarcinoma in the appropriate clinical context.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Brain Neoplasms / diagnosis. Brain Neoplasms / secondary. Diagnostic Errors / prevention & control. Lung Neoplasms / pathology. Tuberculosis, Central Nervous System / diagnosis
  • [MeSH-minor] Aged. Calcinosis / etiology. Calcinosis / pathology. Calcinosis / radiography. Cerebellopontine Angle / pathology. Cerebellopontine Angle / radiography. Diagnosis, Differential. Humans. Lung / pathology. Lung / radiography. Magnetic Resonance Imaging. Male. Telencephalon / pathology. Telencephalon / physiopathology. Telencephalon / radiography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Tuberculosis.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17085301.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


10. Hill HC: Challenges of utilizing immunostains to facilitate the diagnosis and management of metastatic adenocarcinoma. J Natl Med Assoc; 2008 Dec;100(12):1469-73
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Challenges of utilizing immunostains to facilitate the diagnosis and management of metastatic adenocarcinoma.
  • Treatment is based upon the results of several diagnostic radiographic modalities that may locate the occult primary and determine the extent of metastatic tumor burden.
  • We describe metastatic adenocarcinoma of unknown primary presenting as a pericardial effusion and coincident supraclavicular adenopathy.
  • The patient completed the chemotherapy and had stable metastatic tumor burden with an acceptable quality of life.
  • Two years after initial diagnosis, the patient expired because of disease progression.
  • Although immunohistochemical staining initially suggested metastatic breast carcinoma, her clinical course confirmed a lung primary.
  • [MeSH-major] Adenocarcinoma / secondary. Lung Neoplasms / diagnosis. Lung Neoplasms / pathology. Neoplasms, Unknown Primary / diagnosis
  • [MeSH-minor] Adult. Bone Neoplasms / secondary. Brain Neoplasms / secondary. Bromhexine. Fatal Outcome. Female. Humans. Immunohistochemistry. Pericardial Effusion / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Med Assoc. 2009 May;101(5):478 [19476202.001]
  • (PMID = 19110917.001).
  • [ISSN] 1943-4693
  • [Journal-full-title] Journal of the National Medical Association
  • [ISO-abbreviation] J Natl Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q1J152VB1P / Bromhexine
  •  go-up   go-down


11. Serizawa T: Metastatic brain tumors: lung cancer. Prog Neurol Surg; 2009;22:142-53
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic brain tumors: lung cancer.
  • OBJECTIVE: To present the results of gamma knife surgery (GKS) for brain metastases from lung cancer, without whole-brain radiation therapy (WBRT), at Chiba Cardiovascular Center.
  • The lung cancer histologies were adenocarcinoma in 294 patients, squamous cell in 52, small cell in 56, large cell in 9, and others/undetermined in 32.
  • A low Karnofsky performance status (KPS) score, numerous (> 10) brain lesions and carcinomatous meningitis were significant factors influencing QS.
  • CONCLUSION: In terms of NS and QS, GKS alone for metastatic brain tumors from lung cancer provides excellent palliation for selected patients without carcinomatous meningitis.
  • [MeSH-major] Brain Neoplasms / secondary. Brain Neoplasms / surgery. Lung Neoplasms / pathology. Radiosurgery. Small Cell Lung Carcinoma / secondary. Small Cell Lung Carcinoma / surgery


12. Kikuchi T, Daigo Y, Ishikawa N, Katagiri T, Tsunoda T, Yoshida S, Nakamura Y: Expression profiles of metastatic brain tumor from lung adenocarcinomas on cDNA microarray. Int J Oncol; 2006 Apr;28(4):799-805
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profiles of metastatic brain tumor from lung adenocarcinomas on cDNA microarray.
  • To identify genes associated with this complicated biological feature of cancer, we analyzed expression profiles of 16 metastatic brain tumors derived from primary lung adenocarcinoma (ADC) using cDNA microarray representing 23,040 genes.
  • We applied bioinformatic algorithm to compare the expression data of these 16 brain metastatic loci with those of 37 primary NSCLCs including 22 ADCs, and found that metastatic tumor cells has very different characteristics of gene expression patterns from primary ones.
  • Two hundred and forty-four genes that showed significantly different expression levels between the two groups included plasma membrane bounding proteins, cellular antigens, and cytoskeletal proteins that might play important roles in altering cell-cell communication, attachment, and cell motility, and enhance the metastatic ability of cancer cells.
  • Our results provide valuable information for development of predictive markers as well as novel therapeutic target molecules for metastatic brain tumor of ADC of the lung.
  • [MeSH-major] Adenocarcinoma / genetics. Brain Neoplasms / genetics. Gene Expression Profiling. Lung Neoplasms / genetics. Oligonucleotide Array Sequence Analysis / methods
  • [MeSH-minor] Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Non-Small-Cell Lung / pathology. Cluster Analysis. Gene Expression Regulation, Neoplastic / genetics. Humans

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16525627.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


13. Ferrer N, Cobo M, Paredes A, Méndez M, Muñoz-Langa J, Rueda A, Álvarez de Mon M, Sánchez-Hernández A, Gallego R, Torrego J: Phase II study of bevacizumab in combination with cisplatin and docetaxel as first-line treatment of patients (p) with metastatic non-squamous non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):e19023

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of bevacizumab in combination with cisplatin and docetaxel as first-line treatment of patients (p) with metastatic non-squamous non-small cell lung cancer (NSCLC).
  • METHODS: Eligibility criteria: chemo- naïve, stage IIIB wet or IV, non-squamous NSCLC, PS 0-1, no brain metastases and no history of gross hemoptysis.
  • RESULTS: 50 p were enrolled (enrollment completed): 24% female, median age 60 (36-74), PS 1: 64%, adenocarcinoma: 72%; stage IV: 92%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962586.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Edelman MJ, Belani CP, Socinski MA, Ansari R, Obasaju CK, Monberg MJ, Chen R, Treat J: Incidence and outcomes associated with brain metastases (BM) in a three-arm phase III trial of gemcitabine in combination with carboplatin (GC) or paclitaxel (GP) versus paclitaxel plus carboplatin (PC) for advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):8076

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and outcomes associated with brain metastases (BM) in a three-arm phase III trial of gemcitabine in combination with carboplatin (GC) or paclitaxel (GP) versus paclitaxel plus carboplatin (PC) for advanced non-small cell lung cancer (NSCLC).
  • : 8076 Background: A limited number of randomized phase III studies of advanced or metastatic NSCLC have included a mixed population of patients (pts) with and without BM at presentation.
  • Analyses of pts with lung cancer from the 1970s and 1980s indicated that the incidence of BM at the time of diagnosis was approximately 10%.
  • Pts who developed BM as the only evidence of progression were able to be treated with whole brain radiation and steroids and remained on study.
  • 1) The higher incidence of BM (17.1%) observed in this trial may be related to the increasing incidence of adenocarcinoma, or to the increasing sensitivity of imaging modalities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962650.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Virani S, Almubarak M, Marano G, Rogers JS: Role of PET/CT scanning in detecting asymptomatic brain metastases in non-small cell lung cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e19038

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of PET/CT scanning in detecting asymptomatic brain metastases in non-small cell lung cancer.
  • : e19038 Background: Up to one-third of non-small cell lung cancer (NSCLC) patients are diagnosed with brain metastasis.
  • Our study aims to evaluate the role of whole body and brain FDG-PET/CT in detecting asymptomatic brain metastasis in this population.
  • METHODS: We performed a retrospective chart review of 282 consecutive non-small cell lung cancer patients between February of 2005 and June of 2008.
  • 60 patients with brain metastasis were identified.
  • Information regarding tumor histology and presence of neurological symptoms at the time of discovery of brain metastasis was collected.
  • In addition, data was acquired from brain MRI and PET/CT (with IV contrast) reports including: study date, findings and any change in staging secondary to the study.
  • 39 (65%) of the patients had neurological symptoms at the time of discovery of brain metastasis.
  • PET/CT scan with IV contrast was performed in 53 patients with brain metastasis.
  • For patients who had a PET/CT scan, the histological types were: adenocarcinoma (58.4%), unclassified (22.6%), squamous (13.2%), large cell (3.8%) and other (1.8%).
  • PET/CT scan had a sensitivity of 97.8% in detecting CNS metastasis seen on brain MRI.
  • 19/53 patients were found to have asymptomatic brain metastasis on PET/CT scan (2 stage I, 1 stage II, 2 stage III and 13 stage IV).
  • CONCLUSIONS: PET/CT scan with IV contrast has a high sensitivity in detecting brain metastasis in patients with NSCLC when compared to brain MRI.
  • It is effective in detecting asymptomatic brain metastasis in this population.
  • Those patients, who initially were thought to have non-metastatic disease, are spared inappropriate aggressive surgery or radiation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962123.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Castellano MC, Massone AR, Idiart JR: Primary pulmonary adenocarcinoma metastatic to the uvea, brain and adrenal gland in a dog. J Vet Med A Physiol Pathol Clin Med; 2006 May;53(4):194-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary pulmonary adenocarcinoma metastatic to the uvea, brain and adrenal gland in a dog.
  • On necropsy, lung masses and nodules in left iris, right adrenal medulla, and brain were detected.
  • Histologically the primary tumour was diagnosed as pulmonary adenocarcinoma with predominant solid pattern.
  • Metastases to regional lymph nodes, uvea, adrenal medulla, and brain were recognized.
  • The metastatic behaviour resembled that occurring in humans.
  • To the authors' knowledge, this is the first report of a pulmonary adenocarcinoma with metastasis to the uvea in a dog.
  • [MeSH-major] Adenocarcinoma / veterinary. Brain Neoplasms / veterinary. Dog Diseases / pathology. Lung Neoplasms / veterinary. Uveal Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16629953.001).
  • [ISSN] 0931-184X
  • [Journal-full-title] Journal of veterinary medicine. A, Physiology, pathology, clinical medicine
  • [ISO-abbreviation] J Vet Med A Physiol Pathol Clin Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


17. Sato T, Soejima K, Nakayama S, Satomi R, Sayama K, Asano K: [A case of fat embolism syndrome associated with pathological femoral fracture caused by metastatic adenocarcinoma of the lung]. Nihon Kokyuki Gakkai Zasshi; 2010 Oct;48(10):765-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of fat embolism syndrome associated with pathological femoral fracture caused by metastatic adenocarcinoma of the lung].
  • A 76-year-old woman with multiple bone metastases from lung adenocarcinoma was admitted due to a pathological femoral fracture.
  • Computed tomography of the chest revealed diffuse ground glass opacities in both lungs, and magnetic resonance imaging of the brain showed multiple acute infarctions.
  • Fat embolism syndrome should be considered as a differential diagnosis if consciousness disturbance and respiratory failure occur in patients with metastatic bone carcinoma and pathological long bone fractures.
  • [MeSH-major] Adenocarcinoma / complications. Embolism, Fat / etiology. Femoral Fractures / etiology. Fractures, Spontaneous / etiology. Lung Neoplasms / complications

  • Genetic Alliance. consumer health - Embolism.
  • MedlinePlus Health Information. consumer health - Leg Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21066866.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


18. Omlin A, D'Addario G, Gillessen S, Cerny T, von Hessling A, Früh M: Activity of pemetrexed against brain metastases in a patient with adenocarcinoma of the lung. Lung Cancer; 2009 Sep;65(3):383-4
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activity of pemetrexed against brain metastases in a patient with adenocarcinoma of the lung.
  • A 53-year-old woman was with adenocarcinoma of the lung metastatic to the brain was treated after several lines of chemotherapy with pemetrexed.
  • After six cycles an impressive regression of the brain metastases was documented.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Antimetabolites, Antineoplastic / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Glutamates / therapeutic use. Guanine / analogs & derivatives. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. FOLIC ACID .
  • Hazardous Substances Data Bank. CYANOCOBALAMIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19375814.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; 935E97BOY8 / Folic Acid; P6YC3EG204 / Vitamin B 12
  •  go-up   go-down


19. Hariharan S, Zhu J, Nadkarni MA, Donahue JE: Metastatic lung cancer in the cerebellopontine angles mimicking bilateral acoustic neuroma. J Clin Neurosci; 2005 Feb;12(2):184-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic lung cancer in the cerebellopontine angles mimicking bilateral acoustic neuroma.
  • MRI revealed bilateral enhancing CPA lesions, which were suggestive of acoustic neuromas and a diagnosis of NF-2.
  • However, autopsy showed metastatic adenocarcinoma of the lung.
  • Therefore, metastatic carcinoma to the CPA can mimic bilateral acoustic neuromas; imaging studies alone may be insufficient to diagnose NF-2.
  • [MeSH-major] Adenocarcinoma / secondary. Brain Neoplasms / secondary. Cerebellopontine Angle / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Neuroma, Acoustic


20. Naugler C, Xu Z: Pancreatic adenocarcinoma metastatic to the pineal gland. J Clin Neurosci; 2008 Nov;15(11):1284-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic adenocarcinoma metastatic to the pineal gland.
  • Metastases to the pineal gland are rare and reported cases have consisted primarily of gastrointestinal and lung primary malignancies.
  • Here we present the case of a 66-year-old female with autosomal dominant polycystic kidney and liver disease who was found at autopsy to have an unrecognized infiltrating ductal adenocarcinoma of the pancreas with metastases to the liver, lungs and pineal gland.
  • As far as we are aware, this is the first report of a metastasis of infiltrating ductal adenocarcinoma of the pancreas to the pineal gland.
  • [MeSH-major] Adenocarcinoma / pathology. Brain Neoplasms / secondary. Pancreatic Neoplasms / pathology. Pineal Gland. Pinealoma / secondary

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18829324.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


21. Kai N, Ishii H, Morinag R, Sonoda H, Oka H, Amemiya Y, Iwata A, Otani S, Umeki K, Sakashita H, Kadota J: [Pulmonary adenocarcinoma with facial nerve palsy as the first sign of onset due to a metastatic temporal bone tumor]. Nihon Kokyuki Gakkai Zasshi; 2009 Apr;47(4):304-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary adenocarcinoma with facial nerve palsy as the first sign of onset due to a metastatic temporal bone tumor].
  • Brain magnetic resonance imaging showed a mass lesion with a well-enhanced margin in the left temporal bone.
  • A computed tomographic scan of the chest showed a lung mass in the left lower lobe, which was thereafter diagnosed as adenocarcinoma.
  • An immunohistochemical examination of the tissue specimen obtained from the left temporal bone revealed evidence of metastatic adenocarcinoma from the lung.
  • No other metastatic lesions including separate site of bone were seen.
  • This is a very rare case of lung cancer with facial nerve palsy as the first sign of onset due to a metastatic temporal bone tumor.
  • [MeSH-major] Adenocarcinoma / pathology. Facial Paralysis / etiology. Lung Neoplasms / pathology. Skull Neoplasms / secondary. Temporal Bone

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19455960.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


22. Zohrabian VM, Nandu H, Gulati N, Khitrov G, Zhao C, Mohan A, Demattia J, Braun A, Das K, Murali R, Jhanwar-Uniyal M: Gene expression profiling of metastatic brain cancer. Oncol Rep; 2007 Aug;18(2):321-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling of metastatic brain cancer.
  • Gene expression profiling of metastatic brain tumors from primary lung adenocarcinoma, using a 17k-expression array, revealed that 1561 genes were consistently altered.
  • Genes involved in apoptosis, such as caspase 2 (CASP2), transforming growth factor-beta inducible early gene (TIEG), and neuroprotective heat shock protein 70 (Hsp70) were underexpressed in metastatic brain tumors.
  • Brain-specific angiogenesis inhibitors 1 and 3 (BAI1 and BAI3) were underexpressed as well.
  • The results demonstrated that genes involved in adhesion, motility, and angiogenesis were consistently up-regulated in metastatic brain tumors, while genes involved in apoptosis, neuroprotection, and suppression of angiogenesis were markedly down-regulated, collectively making these cancer cells prone to metastasis.
  • [MeSH-major] Brain Neoplasms / metabolism. Gene Expression Profiling
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / secondary. Humans. Lung Neoplasms / genetics. Lung Neoplasms / pathology. Models, Biological. Oligonucleotide Array Sequence Analysis / methods. Reverse Transcriptase Polymerase Chain Reaction / methods


23. Mujoomdar A, Austin JH, Malhotra R, Powell CA, Pearson GD, Shiau MC, Raftopoulos H: Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma: primary tumor size, cell type, and lymph node metastases. Radiology; 2007 Mar;242(3):882-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma: primary tumor size, cell type, and lymph node metastases.
  • PURPOSE: To retrospectively assess possible clinical predictors of metastatic disease to the brain in patients with non-small cell lung carcinoma (NSCLC).
  • Hierarchical logistic regression was used to determine the predicted probability of metastatic disease to the brain as a function of patient age and sex and of size, cell type, peripheral versus central location, and lymph node stage of the primary NSCLC.
  • RESULTS: Ninety-five (36%) patients had evidence of metastatic disease to the brain.
  • Cell types included adenocarcinoma (136 [52%] patients), undifferentiated (68 [26%] patients), and squamous (47 [18%] patients), for which metastatic disease to the brain occurred in 43%, 41%, and 13% (P = .003) of patients, respectively.
  • The predicted probability of metastatic disease to the brain correlated positively with size of the primary tumor (P < .001), cell type (adenocarcinoma and undifferentiated vs squamous, P = .001), and lymph node stage (P < .017) but did not correlate with age, sex, or primary tumor location.
  • For primary adenocarcinoma without lymph node spread, the predicted probabilities of metastatic disease to the brain from 2- and 6-cm primary tumors were .14 (95% confidence interval: .06, .27) and .72 (95% confidence interval: .48, .88), respectively (P < .02).
  • CONCLUSION: The probability of metastatic disease to the brain from primary NSCLC is correlated with size of the primary tumor, cell type, and intrathoracic lymph node stage.
  • [MeSH-major] Brain Neoplasms / epidemiology. Brain Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / epidemiology. Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / epidemiology. Risk Assessment / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17229875.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


24. Nguyen DX, Chiang AC, Zhang XH, Kim JY, Kris MG, Ladanyi M, Gerald WL, Massagué J: WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell; 2009 Jul 10;138(1):51-62
eagle-i research resources. PMID 19576624 (Special Collections) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis.
  • Metastasis from lung adenocarcinoma can occur swiftly to multiple organs within months of diagnosis.
  • The mechanisms that confer this rapid metastatic capacity to lung tumors are unknown.
  • Activation of the canonical WNT/TCF pathway is identified here as a determinant of metastasis to brain and bone during lung adenocarcinoma progression.
  • Gene expression signatures denoting WNT/TCF activation are associated with relapse to multiple organs in primary lung adenocarcinoma.
  • Metastatic subpopulations isolated from independent lymph node-derived lung adenocarcinoma cell lines harbor a hyperactive WNT/TCF pathway.
  • Reduction of TCF activity in these cells attenuates their ability to form brain and bone metastases in mice, independently of effects on tumor growth in the lungs.
  • Thus, a distinct WNT/TCF signaling program through LEF1 and HOXB9 enhances the competence of lung adenocarcinoma cells to colonize the bones and the brain.


25. Ruppert AM, Beau-Faller M, Neuville A, Guerin E, Voegeli AC, Mennecier B, Legrain M, Molard A, Jeung MY, Gaub MP, Oudet P, Quoix E: EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up. Eur Respir J; 2009 Feb;33(2):436-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up.
  • The epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) erlotinib improves survival of lung cancer as second- or third-line therapy.
  • The present study reports the case of a 27-yr-old nonsmoking male presenting with a metastatic lung adenocarcinoma with EGFR exon 19 deletion, associated with sensitivity to EGFR-TKI.
  • After stopping EGFR-TKI, brain metastases with carcinomatous meningitis were diagnosed.
  • The present report underscores the interest of molecular monitoring in lung cancer.
  • Questions remain concerning the selection of sub-clones during epidermal growth factor receptor tyrosine kinase inhibitor therapy, which could differ according to metastatic sites, especially in the central nervous system.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Central Nervous System Neoplasms / secondary. Central Nervous System Neoplasms / therapy. Lung Neoplasms / pathology. Lung Neoplasms / therapy. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, Epidermal Growth Factor / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19181917.001).
  • [ISSN] 1399-3003
  • [Journal-full-title] The European respiratory journal
  • [ISO-abbreviation] Eur. Respir. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


26. Hu L, Zhang J, Zhu H, Min J, Feng Y, Zhang H: Biological characteristics of a specific brain metastatic cell line derived from human lung adenocarcinoma. Med Oncol; 2010 Sep;27(3):708-14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biological characteristics of a specific brain metastatic cell line derived from human lung adenocarcinoma.
  • To study the expression of VEGF, MMP-9, EGFR, and S100B in a highly brain metastases sub-clone cell line, PC14/B.
  • The in vitro metastases-related behaviors of PC14 /B cells, such as adhesion to extracellular matrix (ECM), migration, and invasion were determined and compared with primary PC14 cells and A549 cells that do not metastasize to brain.
  • The expression of EGFR in PC14/B cells may have negative correlation with their capacities of metastasizing to brain.
  • The specific expression of S100B in PC14/B cells strongly suggest that S100B might be a potential target for developing new therapy to brain metastases of lung cancer.
  • [MeSH-major] Adenocarcinoma / secondary. Brain Neoplasms / secondary. Cell Line, Tumor / metabolism. Lung Neoplasms / pathology. Neoplasm Proteins / biosynthesis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19669609.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Nerve Growth Factors; 0 / S100 Calcium Binding Protein beta Subunit; 0 / S100 Proteins; 0 / S100B protein, human; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


27. Badia Castello M, Trujillano Cabello J, Serviá Goixart L, Tarragona Foradada J, Panades Siurana MJ, Amoròs Galito E: Occult donor metastatic adenocarcinoma. Contribution of the forensic autopsy. A case report. Ann Transplant; 2010 Jan-Mar;15(1):67-71
MedlinePlus Health Information. consumer health - Organ Donation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occult donor metastatic adenocarcinoma. Contribution of the forensic autopsy. A case report.
  • CASE REPORT: Donor was a 75-year-old man with traumatic brain injury caused by an accidental fall, which led to brain death.
  • The forensic autopsy conducted on the following day revealed a suspicious spot in the lung, on which a biopsy was done.
  • Histological examination confirmed the presence of a metastatic adenocarcinoma in the lung 7 days after both kidneys had been transplanted.
  • [MeSH-major] Adenocarcinoma / etiology. Kidney Transplantation / adverse effects. Neoplasms / etiology. Nephrectomy / adverse effects. Tissue Donors
  • [MeSH-minor] Aged. Autopsy. Brain Death / pathology. Humans. Male. Risk

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20305322.001).
  • [ISSN] 2329-0358
  • [Journal-full-title] Annals of transplantation
  • [ISO-abbreviation] Ann. Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


28. Idei M, Urasaki E, Yokota A: [Metastatic brain tumor originating from urachal carcinoma: case report]. No Shinkei Geka; 2005 Oct;33(10):1015-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metastatic brain tumor originating from urachal carcinoma: case report].
  • The authors presented a patient with metastatic brain tumor originating from urachal carcinoma.
  • The brain lesion was suspected to have metasta sized metastatic from urachal carcinoma, and was excised by craniotomy.
  • Histology of the brain tumor was identical to that of urachal carcinoma.
  • Postoperatively the patient received local radiation therapy, but died of multiple metastasis to lung and local recurrence, 18 months later.
  • Though this rare tumor carries a poor prognosis, it may be effective for longer survival of a patient to treat the metastatic brain lesion with surgery and radiation.
  • [MeSH-major] Adenocarcinoma / secondary. Brain Neoplasms / radiotherapy. Brain Neoplasms / secondary. Urachus. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16223181.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


29. Iwakawa R, Kohno T, Anami Y, Noguchi M, Suzuki K, Matsuno Y, Mishima K, Nishikawa R, Tashiro F, Yokota J: Association of p16 homozygous deletions with clinicopathologic characteristics and EGFR/KRAS/p53 mutations in lung adenocarcinoma. Clin Cancer Res; 2008 Jun 15;14(12):3746-53
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of p16 homozygous deletions with clinicopathologic characteristics and EGFR/KRAS/p53 mutations in lung adenocarcinoma.
  • PURPOSE: The p16 gene is frequently inactivated in lung adenocarcinoma.
  • The purpose of this study was to elucidate the prevalence and the timing for the occurrence of p16 HDs in lung adenocarcinoma progression in vivo.
  • EXPERIMENTAL DESIGN: Multiple ligation-dependent probe amplification was used for the detection of p16 HDs in 28 primary small-sized lung adenocarcinomas and 22 metastatic lung adenocarcinomas to the brain.
  • Cancer cells were isolated from primary adenocarcinoma specimens by laser capture microdissection.
  • RESULTS: HDs were detected in 8 of 28 (29%) primary tumors, including 2 of 8 (25%) noninvasive bronchioloalveolar carcinomas, and 5 of 22 (26%) brain metastases, respectively.
  • CONCLUSIONS: p16 HDs occur early in the development of lung adenocarcinomas and with similar frequencies among EGFR type, KRAS type, and non-EGFR/KRAS type lung adenocarcinomas.
  • Tobacco carcinogens would not be a major factor inducing p16 HDs in lung adenocarcinoma progression.
  • [MeSH-major] Adenocarcinoma / genetics. Gene Deletion. Genes, erbB-1. Genes, p16. Genes, p53. Genes, ras. Lung Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18559592.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


30. Varga I, Hutóczki G, Petrás M, Scholtz B, Mikó E, Kenyeres A, Tóth J, Zahuczky G, Bognár L, Hanzély Z, Klekner A: Expression of invasion-related extracellular matrix molecules in human glioblastoma versus intracerebral lung adenocarcinoma metastasis. Cent Eur Neurosurg; 2010 Nov;71(4):173-80
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of invasion-related extracellular matrix molecules in human glioblastoma versus intracerebral lung adenocarcinoma metastasis.
  • Tumor cell invasion into the surrounding brain tissue is mainly responsible for the failure of radical surgical resection, with tumor recurrence in the form of microdisseminated disease.
  • The extent of infiltration of the healthy brain by malignant tumors strongly depends on the tumor cell type.
  • Malignant gliomas show much more intensive peritumoral invasion than do metastatic tumors.
  • Fresh frozen human tissue samples from glioblastoma (GBM), intracerebral lung adenocarcinoma metastasis, and normal brain were evaluated.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Brain Neoplasms / metabolism. Brain Neoplasms / secondary. Extracellular Matrix Proteins / biosynthesis. Glioblastoma / metabolism. Lung Neoplasms / pathology

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Georg Thieme Verlag KG Stuttgart · New York.
  • (PMID = 20397122.001).
  • [ISSN] 1868-4912
  • [Journal-full-title] Central European neurosurgery
  • [ISO-abbreviation] Cent Eur Neurosurg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Extracellular Matrix Proteins; 0 / RNA, Messenger
  •  go-up   go-down


31. Carpentier A, McNichols RJ, Stafford RJ, Itzcovitz J, Guichard JP, Reizine D, Delaloge S, Vicaut E, Payen D, Gowda A, George B: Real-time magnetic resonance-guided laser thermal therapy for focal metastatic brain tumors. Neurosurgery; 2008 Jul;63(1 Suppl 1):ONS21-8; discussion ONS28-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Real-time magnetic resonance-guided laser thermal therapy for focal metastatic brain tumors.
  • OBJECTIVE: We report the initial results of a pilot clinical trial exploring the safety and feasibility of the first real-time magnetic resonance-guided laser-induced thermal therapy of treatment-resistant focal metastatic intracranial tumors.
  • METHODS: Patients with resistant metastatic intracranial tumors who had previously undergone chemotherapy, whole-brain radiation therapy, and radiosurgery and who were recused from surgery were eligible for this trial.
  • CONCLUSION: In this ongoing trial, a total of four patients have had six metastatic tumors treated with laser thermal ablations.
  • Magnetic resonance-guided laser-induced thermal therapy appears to provide a new, efficient treatment for recurrent focal metastatic brain disease.
  • [MeSH-major] Brain Neoplasms / secondary. Brain Neoplasms / surgery. Computer Systems. Hot Temperature / therapeutic use. Laser Therapy / methods. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Aged. Breast Neoplasms / pathology. Female. Follow-Up Studies. Humans. Lung Neoplasms / pathology. Male. Middle Aged. Monitoring, Intraoperative / instrumentation. Monitoring, Intraoperative / methods. Pilot Projects. Stereotaxic Techniques / instrumentation

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18728600.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 2 R44 CA079282; United States / NCI NIH HHS / CA / 2 R44 CA101573; United States / NCI NIH HHS / CA / 2 R44 CA96227; United States / NIA NIH HHS / AG / 5 R44 AG019276
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


32. Imai K, Ashitani J, Yanagi S, Kodama T, Kyoraku Y, Sano A, Matsumoto N, Nakazato M: [A case of lung adenocarcinoma keeping complete remission by treatment with gefitinib]. Nihon Kokyuki Gakkai Zasshi; 2007 Jan;45(1):71-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of lung adenocarcinoma keeping complete remission by treatment with gefitinib].
  • A 74-year-old smoking man was admitted because of lung cancer with metastatic brain tumor.
  • Examinations for lung cancer and brain tumor showed adenocarcinoma (clinical stage IV).
  • Lung tumor disappeared on chest computerized tomography in January 2004 and no recurrence has been detected as of March 2006.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / administration & dosage. Lung Neoplasms / drug therapy. Quinazolines / administration & dosage
  • [MeSH-minor] Aged. Brain Neoplasms / secondary. Brain Neoplasms / surgery. Drug Administration Schedule. Humans. Male. Neoplasm Staging. Radiosurgery. Remission Induction. Smoking

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17313031.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


33. Higuchi Y, Serizawa T, Nagano O, Matsuda S, Ono J, Sato M, Iwadate Y, Saeki N: Three-staged stereotactic radiotherapy without whole brain irradiation for large metastatic brain tumors. Int J Radiat Oncol Biol Phys; 2009 Aug 1;74(5):1543-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three-staged stereotactic radiotherapy without whole brain irradiation for large metastatic brain tumors.
  • PURPOSE: To evaluate the efficacy and toxicity of staged stereotactic radiotherapy with a 2-week interfraction interval for unresectable brain metastases more than 10 cm(3) in volume.
  • PATIENTS AND METHODS: Subjects included 43 patients (24 men and 19 women), ranging in age from 41 to 84 years, who had large brain metastases (> 10 cc in volume).
  • Primary tumors were in the colon in 14 patients, lung in 12, breast in 11, and other in 6.
  • Our results suggest staged stereotactic radiotherapy using our protocol to be a possible alternative for treating large brain metastases.
  • [MeSH-major] Brain Neoplasms / surgery. Radiosurgery / methods
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Breast Neoplasms / pathology. Carcinoma, Renal Cell / mortality. Carcinoma, Renal Cell / pathology. Carcinoma, Renal Cell / secondary. Carcinoma, Renal Cell / surgery. Colonic Neoplasms / pathology. Disease-Free Survival. Female. Humans. Kidney Neoplasms / pathology. Lung Neoplasms / pathology. Male. Middle Aged. Remission Induction. Survival Rate. Tumor Burden

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19135317.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Strickland-Marmol LB, Khoor A, Livingston SK, Rojiani A: Utility of tissue-specific transcription factors thyroid transcription factor 1 and Cdx2 in determining the primary site of metastatic adenocarcinomas to the brain. Arch Pathol Lab Med; 2007 Nov;131(11):1686-90
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of tissue-specific transcription factors thyroid transcription factor 1 and Cdx2 in determining the primary site of metastatic adenocarcinomas to the brain.
  • CONTEXT: Brain metastases of adenocarcinoma of unknown primary pose a diagnostic dilemma to the surgical pathologist.
  • Although the most common source in these cases is the lung, determining a primary source is difficult on routinely stained slides.
  • Recently, attention has turned to tissue-specific transcription factors, such as thyroid transcription factor 1 (TTF-1) and Cdx2, in the appraisal of metastatic adenocarcinomas.
  • OBJECTIVE: To characterize the previously unpublished immunohistochemical expression of the relatively new tissue-specific transcription factor Cdx2 in metastatic adenocarcinomas to the brain.
  • Lee Moffitt Cancer Center and Research Institute, Tampa, Fla, and retrieved 38 consecutive cases of metastatic adenocarcinoma (22 pulmonary, 10 breast, 6 gastrointestinal [2 esophagus/gastroesophageal junction, 4 colorectal]) to the brain with confirmation of the primary site by chart review and histologic evaluation.
  • RESULTS: Specificities and positive predictive values for Cdx2 and TTF-1 equaled 100% for metastatic gastrointestinal and pulmonary adenocarcinomas, respectively.
  • CONCLUSIONS: Cdx2 is a specific and valuable tool for the surgical pathologist when faced with the common problem of metastatic adenocarcinoma of unknown primary.
  • In conjunction with TTF-1, cytokeratin 7, and cytokeratin 20, Cdx2 can accurately differentiate the most common sources of metastatic adenocarcinoma to the brain.
  • [MeSH-major] Adenocarcinoma / secondary. Brain Neoplasms / secondary. DNA-Binding Proteins / metabolism. Homeodomain Proteins / metabolism. Neoplasms, Unknown Primary / diagnosis. Neoplasms, Unknown Primary / metabolism
  • [MeSH-minor] Breast Neoplasms / diagnosis. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. Diagnosis, Differential. Gastrointestinal Neoplasms / diagnosis. Gastrointestinal Neoplasms / metabolism. Gastrointestinal Neoplasms / pathology. Humans. Keratin-20 / metabolism. Keratin-7 / metabolism. Lung Neoplasms / diagnosis. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Predictive Value of Tests. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17979487.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDX2 protein, human; 0 / DNA-Binding Proteins; 0 / Homeodomain Proteins; 0 / Keratin-20; 0 / Keratin-7; 0 / TTF1 protein, human
  •  go-up   go-down


35. Hsieh CT, Chang CF, Liu MY, Chang LP, Hueng DY, Chang SD, Ju DT: Successful treatment of metastatic brain tumor by CyberKnife: a case report. Kaohsiung J Med Sci; 2010 Mar;26(3):144-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of metastatic brain tumor by CyberKnife: a case report.
  • Stereotactic radiosurgery plays an important role in management of metastatic brain tumors, especially when the tumor has recurred after treatment with previous whole brain radiotherapy.
  • Most metastatic brain tumors less than 1 cm(3) show a complete response after stereotactic radio-surgery.
  • However, there are few reports of a dramatic change in the complete response of large metastatic brain tumors.
  • Here, we report a case of adenocarcinoma of lung that had metastasized to the brain.
  • Because the recurrence of the metastatic brain tumor measured approximately 3 cm in diameter, the tumor was previously treated with two prior craniotomies followed by whole brain radiation to the resection cavity.
  • [MeSH-major] Brain Neoplasms / secondary. Brain Neoplasms / surgery. Radiosurgery / methods
  • [MeSH-minor] Humans. Lung Neoplasms / pathology. Male. Middle Aged. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20227654.001).
  • [ISSN] 1607-551X
  • [Journal-full-title] The Kaohsiung journal of medical sciences
  • [ISO-abbreviation] Kaohsiung J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


36. Grinberg-Rashi H, Ofek E, Perelman M, Skarda J, Yaron P, Hajdúch M, Jacob-Hirsch J, Amariglio N, Krupsky M, Simansky DA, Ram Z, Pfeffer R, Galernter I, Steinberg DM, Ben-Dov I, Rechavi G, Izraeli S: The expression of three genes in primary non-small cell lung cancer is associated with metastatic spread to the brain. Clin Cancer Res; 2009 Mar 1;15(5):1755-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression of three genes in primary non-small cell lung cancer is associated with metastatic spread to the brain.
  • PURPOSE: Brain metastases affect 25% of patients with non-small cell lung cancer (NSCLC).
  • We hypothesized that the expression of genes in primary NSCLC tumors could predict brain metastasis and be used for identification of high-risk patients, who may benefit from prophylactic therapy.
  • Univariate and multivariate Cox regression analysis was used to analyze the correlation between gene expression and the occurrence of brain metastasis.
  • RESULTS: A score based on the expression levels of three genes, CDH2 (N-cadherin), KIFC1, and FALZ, was highly predictive of brain metastasis in early and advanced lung cancer.
  • The probability of remaining brain metastasis-free at 2 years after diagnosis was 90.0+/-9.5% for patients with stage I/stage II tumors and low score compared with 62.7+/-12% for patients with high score (P<0.01).
  • In patients with more advanced lung cancer, the brain metastasis-free survival at 24 months was 89% for patients with low score compared with only 37% in patients with high score (P<0.02).
  • CONCLUSIONS: The expression levels of three genes in primary NSCLC tumors may be used to identify patients at high risk for brain metastasis who may benefit from prophylactic therapy to the central nervous system.
  • [MeSH-major] Antigens, CD / genetics. Antigens, Nuclear / genetics. Brain Neoplasms / diagnosis. Cadherins / genetics. Carcinoma, Non-Small-Cell Lung / genetics. Kinesin / genetics. Lung Neoplasms / genetics. Nerve Tissue Proteins / genetics. Transcription Factors / genetics
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Adenocarcinoma / secondary. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / secondary. Female. Gene Expression Profiling. Humans. Immunoenzyme Techniques. Male. Middle Aged. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • Genetic Alliance. consumer health - Brain Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19190132.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Nuclear; 0 / Biomarkers, Tumor; 0 / CDH2 protein, human; 0 / Cadherins; 0 / KIF1C protein, human; 0 / Nerve Tissue Proteins; 0 / RNA, Messenger; 0 / Transcription Factors; 0 / fetal Alzheimer antigen; EC 3.6.1.- / Kinesin
  •  go-up   go-down


37. Ribeiro HB, Paiva TF Jr, Mamprin GP, Gorzoni ML, Rocha AJ, Lancellotti CL: Carcinomatous encephalitis as clinical presentation of occult lung adenocarcinoma: case report. Arq Neuropsiquiatr; 2007 Sep;65(3B):841-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinomatous encephalitis as clinical presentation of occult lung adenocarcinoma: case report.
  • A magnetic resonance imaging (MRI) with gadolinium, the method of choice, presumes the diagnosis.
  • Previous reports of this unusual form of metastatic disease have described patients with prior diagnosis of pulmonary adenocarcinoma.
  • We present the case of carcinomatous encephalitis in a 76-year-old woman as the primary manifestation of occult pulmonary adenocarcinoma with its clinical, imaging, and anatomopathological findings.
  • [MeSH-major] Brain Neoplasms / secondary. Carcinoma, Acinar Cell / secondary. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17952293.001).
  • [ISSN] 0004-282X
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


38. Tabaka J, Nowacki P, Pankowski J: The interaction between lung cancer metastases to the brain and their surroundings. Folia Neuropathol; 2006;44(1):42-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The interaction between lung cancer metastases to the brain and their surroundings.
  • BACKGROUND AND STUDY PURPOSE: due to the fact that an interrelation between metastases of lung cancer to the brain and surroundings may influence the prognosis, we made attempts to answer the following questions:.
  • 2) are there any differences in the glial and vascular reactivity around different forms of lung cancer metastases to the brain?
  • MATERIAL AND METHODS: a neuropathological examination has been done on 66 patients (27 women and 39 men) with lung cancer metastases to the brain.
  • They were divided into three groups: group I - 18 cases of squamous cell lung cancer (sqclc), group II - 33 cases of lung adenocarcinoma (adl) and group III - 15 cases of small cell lung cancer (sclc).
  • RESULTS: the most "aggressive" mode of metastatic infiltration into the brain was presented by sqclc.
  • There were no significant differences in the mean number of vessels within the metastatic surroundings.
  • CONCLUSIONS: a dispersed mode of infiltration by sqclc metastases to the brain causes precise detection of the macroscopic border between the metastatic tumour and the nervous tissue to be much more difficult than in sclc, which is sharply demarcated from the surroundings.
  • The poor prognosis in sqclc metastases to the brain may, among other, depend on metastatic remnants in the form of dispersed neoplastic cells within the seemingly uninvolved nervous tissue, not removed during neurosurgical procedures.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16565930.001).
  • [ISSN] 1641-4640
  • [Journal-full-title] Folia neuropathologica
  • [ISO-abbreviation] Folia Neuropathol
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein
  •  go-up   go-down


39. Ruffatti S, Zanchin G, Maggioni F: A case of intractable facial pain secondary to metastatic lung cancer. Neurol Sci; 2008 Apr;29(2):117-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of intractable facial pain secondary to metastatic lung cancer.
  • Persistent idiopathic facial pain, once called atypical facial pain, rarely anticipates the detection of a lung carcinoma.
  • Thirty-six cases of intractable facial pain secondary to lung neoplasm are described in the literature.
  • The onset of facial pain usually precedes the onset of symptoms and signs due to lung cancer by several months and therefore it should be considered, when present, as a possible marker for an early diagnosis of tumour.
  • We report a case of intractable facial pain associated with metastatic lung cancer in a non-smoker.
  • [MeSH-major] Adenocarcinoma / secondary. Brain Neoplasms / secondary. Facial Pain / etiology. Facial Pain / pathology. Lung Neoplasms / pathology. Pain, Intractable / etiology. Pain, Intractable / pathology


40. Zhang H, Wang Y, Chen Y, Sun S, Li N, Lv D, Liu C, Huang L, He D, Xiao X: Identification and validation of S100A7 associated with lung squamous cell carcinoma metastasis to brain. Lung Cancer; 2007 Jul;57(1):37-45
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification and validation of S100A7 associated with lung squamous cell carcinoma metastasis to brain.
  • To identify potential markers associated with non-small cell lung cancer (NSCLC) metastasis to brain, comparative proteome analysis on two lung squamous cell carcinoma (SCC) cell lines, NCI-H226 and H226Br (the brain metastatic cell line of NCI-H226), was performed using two-dimensional electrophoresis (2-DE) followed by a tandem mass spectrometer with a matrix-assisted laser desorption/ionization (MALDI) source.
  • To determine whether S100A7 overexpression is actually associated with SCC metastasis to brain, S100A7 protein was testified in 10 brain metastasis tissues from NSCLC, 38 primary NSCLC tissues including half matched local positive lymph nodes, 5 primary brain tumors and 2 non-cancer brain tissues by immunohistochemistry.
  • Of particular interest to us was that the positive staining of S100A7 could be found in 3/5 (60%) brain metastases tissue from SCC and 8/21 (38%) the primary lung SCC tissues, while no positive staining was observed in the brain metastases tissue from Ad (n=5), the primary adenocarcinoma (Ad) tissues (n=17), the primary brain tumors (n=5), all local positive lymph nodes from the primary NSCLC (n=19) and non-cancer brain tissues (n=2).
  • These findings suggest that S100A7 expression is closely associated with SCC metastasis to brain and may be a potential biomarker for monitoring the development of SCC.
  • [MeSH-major] Brain Neoplasms / chemistry. Calcium-Binding Proteins / analysis. Carcinoma, Squamous Cell / chemistry. Lung Neoplasms / chemistry. Neoplasm Proteins / analysis
  • [MeSH-minor] Brain / pathology. Carcinoma, Non-Small-Cell Lung / chemistry. Carcinoma, Non-Small-Cell Lung / diagnosis. Carcinoma, Non-Small-Cell Lung / metabolism. Case-Control Studies. Cell Line, Tumor. Humans. Immunohistochemistry. Lymph Nodes / pathology. Neoplasm Metastasis. Peptide Mapping. Proteome / analysis. Proteomics / methods. Reproducibility of Results. S100 Proteins

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17418446.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Calcium-Binding Proteins; 0 / Neoplasm Proteins; 0 / Proteome; 0 / S100 Proteins; 0 / S100A7 protein, human
  •  go-up   go-down


41. Iwasaki T, Okada T, Namba Y, Niinaka M, Takeda Y, Kimura H, Naka Y, Mori M, Nakagawa M, Yokota S, Ito M: [A case of lung cancer with cranial neuropathy as the first sign of onset due to metastatic leptomeningeal carcinomatosis]. Nihon Kokyuki Gakkai Zasshi; 2005 Nov;43(11):664-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of lung cancer with cranial neuropathy as the first sign of onset due to metastatic leptomeningeal carcinomatosis].
  • An abnormal shadow was detected in the right upper lung field and adenocarcinoma of the lung with multiple brain metastases was diagnosed.
  • He underwent gamma-knife radiosurgery for the brain lesions and subsequent systemic chemotherapy consisting of combined carboplatin and paclitaxel, which were not effective.
  • Adenocarcinoma cells confirmed in the cerebrospinal fluid were similar to those in the obtained by transbronchial curetting.
  • Whole-brain irradiation was performed, however, the neurological symptoms worsened and he died.
  • It is thought that cranial neuropathy due to leptomeningeal carcinomatosis is a rare form of onset for lung cancer.
  • [MeSH-major] Adenocarcinoma / secondary. Cranial Nerve Diseases / etiology. Lung Neoplasms / pathology. Meningeal Neoplasms / secondary
  • [MeSH-minor] Aged. Brain / pathology. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16366364.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


42. Arai A, Morishita A, Hanada Y, Aihara H: Solitary metastatic tumor within the optic chiasm--case report. Neurol Med Chir (Tokyo); 2010;50(2):158-61
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary metastatic tumor within the optic chiasm--case report.
  • A 61-year-old female, previously treated for lung cancer, presented with a rare case of metastasis directly to the optic chiasm manifesting as visual deficits.
  • The histological diagnosis was adenocarcinoma, which was consistent with the primary lung cancer.
  • She received whole brain irradiation, resulting in mild improvement of her vision.
  • Suprasellar metastatic tumors to the pituitary gland, pituitary stalk, and hypothalamus are well documented, but solitary metastasis within the optic chiasm should be considered as one of several differential diagnoses of suprasellar tumors, in patients with or without a history of treated cancer.
  • [MeSH-major] Adenocarcinoma / secondary. Lung Neoplasms / pathology. Neoplasm Metastasis / pathology. Optic Chiasm / pathology. Optic Nerve Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20185885.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


43. Daniele L, Cassoni P, Bacillo E, Cappia S, Righi L, Volante M, Tondat F, Inghirami G, Sapino A, Scagliotti GV, Papotti M, Novello S: Epidermal growth factor receptor gene in primary tumor and metastatic sites from non-small cell lung cancer. J Thorac Oncol; 2009 Jun;4(6):684-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor gene in primary tumor and metastatic sites from non-small cell lung cancer.
  • INTRODUCTION: The majority of patients with non-small cell lung cancer (NSCLC) develop distant metastases.
  • Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are capable of reducing brain and adrenal metastases.
  • Among the seven cases FISH-positive at the metastatic site but negative in the primary tumor, six were brain metastases, and one was an adrenal metastasis; all were polysomic for chromosome 7, none were amplified.
  • CONCLUSION: Because the molecular asset of EGFR may change during the metastatic progression of NSCLC to brain (but not to adrenal), the selection of patients with brain metastasis for specific targeted therapies by EGFR FISH analysis should be performed on metastatic lesions rather than on their corresponding primary tumors.
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Brain Neoplasms / genetics. Carcinoma, Non-Small-Cell Lung / genetics. Lung Neoplasms / genetics. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / secondary. Aged. Aged, 80 and over. Carcinoma, Large Cell / genetics. Carcinoma, Large Cell / secondary. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / secondary. Chromosomes, Human, Pair 7 / genetics. DNA, Neoplasm / genetics. DNA, Neoplasm / metabolism. Female. Gene Expression Regulation, Neoplastic. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Prognosis. Small Cell Lung Carcinoma / genetics. Small Cell Lung Carcinoma / secondary. Survival Rate


44. Oneç B, Oksüzoğlu B, Hatipoğlu HG, Oneç K, Azak A, Zengin N: Cavernous sinus syndrome caused by metastatic colon carcinoma. Clin Colorectal Cancer; 2007 Jul;6(8):593-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cavernous sinus syndrome caused by metastatic colon carcinoma.
  • Cranial metastasis has been reported as infrequent during colon cancers and usually occurs in the late stages with liver and/or lung metastasis.
  • In patients with cavernous sinus metastasis, the most common primary sites are the breast, lung, and genitourinary carcinomas, if head and neck tumors are excluded.
  • A 34-year-old man underwent a right hemicolectomy for a mucinous adenocarcinoma of the right colon 14 months before presentation.
  • Because metastatic implants on the omentum were detected during the operation, combination chemotherapy was begun.
  • Primary colon adenocarcinoma with cavernous sinus metastasis is very rare.
  • [MeSH-major] Adenocarcinoma / secondary. Brain Neoplasms / secondary. Cavernous Sinus. Colonic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17681107.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Cassoni P, Daniele L, Maldi E, Righi L, Tavaglione V, Novello S, Volante M, Scagliotti GV, Papotti M: Caveolin-1 expression in lung carcinoma varies according to tumour histotype and is acquired de novo in brain metastases. Histopathology; 2009 Jul;55(1):20-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caveolin-1 expression in lung carcinoma varies according to tumour histotype and is acquired de novo in brain metastases.
  • AIMS: To study caveolin-1 (Cav-1) expression in metastatic lung carcinomas.
  • METHODS AND RESULTS: Cav-1 expression was investigated in a series of 121 lung carcinomas and it was shown that 18/121 tumours (14.9%) were Cav-1+.
  • Moreover, the percentage of Cav-1+ tumours with distant metastases was almost double that of non-metastatic tumours (17.8% vs. 8.1%), irrespective of the histotype.
  • In 34 tumours metastatic to the brain, primary and secondary lesions were compared and 53% of brain metastases were Cav-1+ vs. 20.6% of primaries, indicating a de novo acquisition of Cav-1 expression.
  • This pattern was exclusive to the brain, as it was not acquired in adrenal metastases.
  • CONCLUSIONS: Cav-1 immunoreactivity in lung carcinoma is histotype-dependent and acquired de novo in brain metastases, suggesting a site-specific phenotypic shift in secondary lesions.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Brain Neoplasms / metabolism. Carcinoma, Large Cell / metabolism. Carcinoma, Squamous Cell / metabolism. Caveolin 1 / metabolism. Lung Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19614763.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Caveolin 1; 0 / DNA, Neoplasm; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


46. Gu CS, Liu CY, Wang MC: Brain metastasis of non-small cell lung cancer presenting as sensorineural hearing loss and vertigo. J Chin Med Assoc; 2009 Jul;72(7):382-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain metastasis of non-small cell lung cancer presenting as sensorineural hearing loss and vertigo.
  • We report a case of lung cancer with multiple metastases to the brain and internal auditory canal.
  • Magnetic resonance imaging of the brain revealed multiple intracranial tumors, including of the left-side internal auditory canal, which were interpreted as seeding of metastatic malignancy.
  • Computed tomographic and bronchoscopic biopsy identified an asymptomatic primary pulmonary adenocarcinoma in the right upper lobe of the lungs.
  • This was a rare case of asymptomatic primary pulmonary adenocarcinoma with brain metastases presenting with sudden hearing loss and vertigo.
  • [MeSH-major] Adenocarcinoma / pathology. Brain Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / pathology. Hearing Loss, Sensorineural / etiology. Lung Neoplasms / pathology. Vertigo / etiology


47. Dudek AZ, Kmak KL, Koopmeiners J, Keshtgarpour M: Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer. Lung Cancer; 2006 Jan;51(1):89-96
SciCrunch. DrugBank: Data: Chemical .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
  • BACKGROUND: Only 15% of patients with non-small cell lung cancer (NSCLC) treated with oral epidermal growth factor tyrosine kinase inhibitor gefitinib, as a second-line therapy have objective responses.
  • Fifty percent will have improvement of lung cancer related symptoms.
  • We have performed a retrospective analysis of 76 patients who received gefitinib as a therapy for previously treated metastatic NSCLC at the University of Minnesota Comprehensive Cancer Center in order to describe characteristics of patients who will likely derive benefits from gefitinib therapy.
  • The Log-rank Test and Cox proportional hazards regression were used to assess the effect of the number of previous therapy lines, histology subtype, performance status, gender, stage of disease at initial diagnosis, and presence of skin rash on time to disease progression and overall survival (OS).
  • There were 37 female and 39 male patients; 47 patients had adenocarcinoma, 22 had squamous and 7 had other NSCLC histologies.
  • Six patients had no prior therapy, 23 had one, 32 had two, 8 had three, and 7 had four prior therapies for lung cancer.
  • Patients with brain metastases (26 patients) benefited from gefitinib therapy at least equally well as those without brain metastatic disease.
  • Patients with adenocarcinoma histology with bronchoalveolar features had superior median time to progression versus other lung cancer histology (14 months versus 3 months, p=0.076), which translated into survival advantage in this group >24 months (95% CI: 0.76, 24+) versus 6.6 months (p=0.0096).
  • We suggest that adenocarcinoma with bronchoalveolar features and the presence of skin rash may be used as predictors of gefitinib benefit.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / secondary. Bronchoalveolar Lavage Fluid / cytology. Carcinoma, Non-Small-Cell Lung / secondary. Exanthema / chemically induced. Lung Neoplasms / pathology. Quinazolines / therapeutic use


48. Omuro AM, Kris MG, Miller VA, Franceschi E, Shah N, Milton DT, Abrey LE: High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer; 2005 Jun 1;103(11):2344-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib.
  • BACKGROUND: Gefitinib is an epidermal growth factor receptor tyrosine kinase inhibitor that induces an early and dramatic response in 10% of patients with advanced nonsmall cell lung carcinoma (NSCLC).
  • They focused on patterns of disease recurrence, risk of brain metastases (BM) and leptomeningeal metastasis (LM), and long-term outcome after initial response to gefitinib.
  • All responders had adenocarcinoma.
  • In 9 (43%) patients, the initial site of disease recurrence was the lung and in 1 it was the liver and bone.
  • Four (57%) of the patients with disease recurrence in the CNS had lung disease under control.
  • Intrinsic resistance of metastatic clones, incomplete CNS penetrance of the drug, and longer survival are possible explanations for this high incidence.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / drug therapy. Meningeal Neoplasms / secondary. Quinazolines / therapeutic use

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15844174.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


49. Gomez-Roca C, Raynaud CM, Penault-Llorca F, Mercier O, Commo F, Morat L, Sabatier L, Dartevelle P, Taranchon E, Besse B, Validire P, Italiano A, Soria JC: Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites. J Thorac Oncol; 2009 Oct;4(10):1212-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites.
  • The correlation of biomarker expression between the primary tumor and its corresponding metastasis has not yet been well documented and analyzed in patients with non-small cell lung cancer (NSCLC).
  • The ERCC1 status was discordant in 20 cases (41%), with a trend toward overexpression in brain and adrenal metastases (p = 0.01 and p = 0.08, respectively).
  • [MeSH-major] Adrenal Gland Neoplasms / metabolism. Biomarkers, Tumor / metabolism. Bone Neoplasms / metabolism. Brain Neoplasms / metabolism. Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / metabolism. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Large Cell / metabolism. Carcinoma, Large Cell / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. DNA-Binding Proteins / metabolism. Endonucleases / metabolism. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Staging. Prognosis. Receptor, Epidermal Growth Factor / metabolism. Receptors, Vascular Endothelial Growth Factor / metabolism. Survival Rate. Vascular Endothelial Growth Factor A / metabolism


50. Ogawa Y, Sugawara T, Seki H, Sakuma T: Thyroid follicular carcinoma metastasized to the lung, skull, and brain 12 years after initial treatment for thyroid gland--case report. Neurol Med Chir (Tokyo); 2006 Jun;46(6):302-5
Hazardous Substances Data Bank. LEVOTHYROXINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid follicular carcinoma metastasized to the lung, skull, and brain 12 years after initial treatment for thyroid gland--case report.
  • A 65-year-old woman presented with multiple metastases from thyroid follicular carcinoma to the lung, skull, and brain.
  • The skull and brain tumors had been successfully treated by surgery, thyroxine supplementation, and radiosurgery until she died of sudden intracerebral hemorrhage which had no connection with tumor treatment.
  • The lung tumor was treated by conventional irradiation and radioactive ablation.
  • Follicular carcinoma is thought to have the most optimistic prognosis even with metastases to the lymph nodes and lung.
  • Radioactive ablation using iodine-131 is widely used to treat the primary and/or metastatic lesion.
  • However, the prognosis for patients with brain metastases is poor.
  • Surgical excision of the metastatic intracranial lesion may be the only effective treatment.
  • [MeSH-major] Adenocarcinoma, Follicular / secondary. Brain Neoplasms / secondary. Epidural Neoplasms / secondary. Lung Neoplasms / secondary. Postoperative Complications / pathology. Radiosurgery. Skull Neoplasms / secondary. Thyroid Neoplasms / radiotherapy. Thyroid Neoplasms / surgery
  • [MeSH-minor] Aged. Cerebral Hemorrhage / pathology. Combined Modality Therapy. Female. Humans. Iodine Radioisotopes / therapeutic use. Lung / pathology. Occipital Bone / pathology. Occipital Bone / surgery. Occipital Lobe / pathology. Occipital Lobe / surgery. Parietal Bone / pathology. Parietal Bone / surgery. Thyroidectomy. Thyroxine / administration & dosage

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16794352.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; Q51BO43MG4 / Thyroxine
  •  go-up   go-down


51. Recchia F, Candeloro G, Necozione S, Bratta M, Bisegna R, Rea S: Alternating XELFOX and XELFIRI in patients with metastatic colorectal cancer. Am J Clin Oncol; 2008 Aug;31(4):323-8
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alternating XELFOX and XELFIRI in patients with metastatic colorectal cancer.
  • BACKGROUND: To evaluate the antitumor activity and toxicity of 5-fluorouracil (FU)/leucovorin (LV) and capecitabine (C) given with either oxaliplatin (OX) or camptothecin (CPT-11) in the treatment of chemotherapy naive patients with metastatic colorectal cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Camptothecin / administration & dosage. Capecitabine. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Humans. Leucovorin / administration & dosage. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Middle Aged. Organoplatinum Compounds / administration & dosage. Prognosis. Prospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18845989.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


52. Wu PF, Kuo KT, Kuo LT, Lin YT, Lee WC, Lu YS, Yang CH, Wu RM, Tu YK, Tasi JC, Tseng HM, Tseng SH, Cheng AL, Lin CH: O(6)-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers. Lung Cancer; 2010 Jun;68(3):484-90
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] O(6)-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers.
  • Since there is great interest in pursuing the potential role of temozolomide, a novel alkylating agent, in the treatment of brain metastases, this study aimed to evaluate MGMT expression as well as its prognostic value in this devastating disease.
  • We studied the expression and methylation status of MGMT in 86 brain metastases of lung cancers.
  • Twenty of them had matched primary lung tumor tissues available for direct comparison.
  • Positive nuclear MGMT expression was detected more frequently in brain metastases as compared with primary lung cancers (83% versus 50%, P=0.004).
  • The discordance in MGMT expression persisted in the 20 paired primary and metastatic tumors (P=0.031).
  • Both univariate and multivariate analyses showed that median overall survival was significantly longer in patients with positive MGMT expression in brain metastases (16.5 versus 3.5 months, P<0.001).
  • In conclusion, MGMT expression was enhanced in brain metastases as compared with the primary lung cancers.
  • MGMT expression in brain metastases was significantly correlated with better survival.
  • [MeSH-major] Adenocarcinoma / diagnosis. Brain Neoplasms / diagnosis. DNA Modification Methylases / metabolism. DNA Repair Enzymes / metabolism. Lung Neoplasms / diagnosis. Tumor Suppressor Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19740564.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Tumor Suppressor Proteins; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


53. Lee HG, Lee B, Kim SM, Suh BJ, Yu HJ: A case of gastric adenocarcinoma presenting as meningeal carcinomatosis. Korean J Intern Med; 2007 Dec;22(4):304-7
Hazardous Substances Data Bank. D-MANNITOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of gastric adenocarcinoma presenting as meningeal carcinomatosis.
  • The most common cancers involving the leptomeninges are breast, lung cancer and melanoma.
  • However, gastric adenocarcinoma has been rarely reported with leptomeningeal carcinomatosis.
  • The endoscopy showed a thickening of the folds of the stomach compatible with the diagnosis of a Borrman type IV gastric cancer.
  • The MRI of brain showed no abnormal findings; however, the patient complained of an intractable persistent headache, nausea and vomiting on admission day 6.
  • The cytology examination of the cerebrospinal fluid supported the diagnosis of metastatic signet ring cell carcinoma.
  • [MeSH-major] Carcinoma, Signet Ring Cell / diagnosis. Meningeal Neoplasms / diagnosis. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3394-402 [10589750.001]
  • [Cites] Am J Clin Oncol. 2003 Apr;26(2):165-70 [12714889.001]
  • [Cites] Jpn J Clin Oncol. 2003 Dec;33(12):608-12 [14769837.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):167-74 [15015782.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):255-60 [16344918.001]
  • [Cites] Neurology. 1999 Jul 22;53(2):382-5 [10430430.001]
  • [Cites] J Neurooncol. 1999 May;43(1):59-62 [10448872.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2005 May;17(5):577-9 [15827450.001]
  • [Cites] J Clin Neurosci. 2005 Apr;12(3):315-8 [15851093.001]
  • [Cites] Ann Oncol. 2004;15 Suppl 4:iv285-91 [15477323.001]
  • (PMID = 18309694.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 3OWL53L36A / Mannitol
  • [Other-IDs] NLM/ PMC2687665
  •  go-up   go-down


54. Marchi N, Mazzone P, Fazio V, Mekhail T, Masaryk T, Janigro D: ProApolipoprotein A1: a serum marker of brain metastases in lung cancer patients. Cancer; 2008 Mar 15;112(6):1313-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ProApolipoprotein A1: a serum marker of brain metastases in lung cancer patients.
  • BACKGROUND: Central nervous system (CNS) diagnostics is a promising tool for detection of neurological disorders, including brain metastases.
  • One of the earliest applications of CNS diagnostics was based on serum markers of blood-brain barrier (BBB) dysfunction, which often correlates with acute, chronic, or incipient brain disease.
  • In the case of brain metastases, serum levels of S100beta demonstrated a good negative predictive value comparable to radiologic investigations.
  • METHODS: Of 103 patients enrolled in a lung cancer study, greater than 50% presented with magnetic resonance imaging (MRI) changes consistent with chronic cerebrovascular disease and reflected by elevated serum S100beta.
  • To unveil serum protein, the authors used proteomic techniques that allow discrimination between patients with brain metastases and lung cancer patients affected by cerebrovascular ischemic changes without infiltrating tumor.
  • RESULTS: ProApolipoprotein A1, transferrin, haptoglobin, and transthyretin were upregulated in patients affected by chronic cerebrovascular disease and brain metastases compared with those affected only by vascular diseases.
  • CONCLUSIONS: In conclusion, these data support the use of serum markers for the early detection of brain metastases.
  • ProApolipoprotein A1 may be used in conjunction with S100beta for serum-based, MRI-independent diagnosis of metastatic brain tumors.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 American Cancer Society.
  • [Cites] J Lipid Res. 1995 Feb;36(2):211-28 [7751809.001]
  • [Cites] Int J Oncol. 2007 Apr;30(4):849-55 [17332923.001]
  • [Cites] Electrophoresis. 1997 Jan;18(1):122-6 [9059833.001]
  • [Cites] J Thorac Cardiovasc Surg. 2000 Jan;119(1):138-47 [10612773.001]
  • [Cites] Ann Thorac Surg. 1999 Dec;68(6):2202-8 [10617003.001]
  • [Cites] J Comp Neurol. 2000 May 15;420(4):445-65 [10805920.001]
  • [Cites] Biochemistry. 2001 Mar 13;40(10):3101-8 [11258924.001]
  • [Cites] Biochim Biophys Acta. 2001 Mar 30;1531(1-2):4-46 [11278170.001]
  • [Cites] Shock. 2001 Aug;16(2):97-101 [11508872.001]
  • [Cites] Pathol Res Pract. 2002;198(1):59-63 [11866213.001]
  • [Cites] Eur J Med Res. 2002 Apr 30;7(4):164-70 [12010651.001]
  • [Cites] Brain Res. 2002 Jun 14;940(1-2):102-4 [12020881.001]
  • [Cites] J Neurol. 2002 Oct;249(10):1357-69 [12382150.001]
  • [Cites] J Neurosci. 2003 Mar 1;23(5):1949-55 [12629200.001]
  • [Cites] Cancer. 2003 Jun 1;97(11):2806-13 [12767094.001]
  • [Cites] Restor Neurol Neurosci. 2003;21(3-4):109-21 [14530574.001]
  • [Cites] Ann Thorac Surg. 2004 Jul;78(1):46-52; discussion 52-3 [15223400.001]
  • [Cites] Obstet Gynecol. 1971 Sep;38(3):427-35 [4999312.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Jan;81(1):66-70 [6198645.001]
  • [Cites] Biochem Biophys Res Commun. 1984 Feb 14;118(3):934-42 [6422932.001]
  • [Cites] Clin Biochem. 1984 Feb;17(1):39-41 [6200254.001]
  • [Cites] Eur J Cancer Clin Oncol. 1984 May;20(5):625-30 [6539699.001]
  • [Cites] J Lipid Res. 1985 Feb;26(2):185-93 [3989377.001]
  • [Cites] Neurosurg Rev. 1989;12(2):91-106 [2674770.001]
  • [Cites] Brain Res Dev Brain Res. 1993 Apr 16;72(2):181-92 [8485842.001]
  • [Cites] Arch Pathol Lab Med. 1994 May;118(5):557-61 [8192564.001]
  • [Cites] J Magn Reson Imaging. 1999 Sep;10(3):254-9 [10508284.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):963-5 [15709159.001]
  • [Cites] Cancer. 2005 Aug 15;104(4):817-24 [15971200.001]
  • [Cites] Proteomics. 2005 Nov;5(17):4589-96 [16237736.001]
  • [Cites] Proteomics. 2006 Jan;6(2):538-46 [16342242.001]
  • [Cites] World J Gastroenterol. 2006 Mar 14;12(10):1536-44 [16570345.001]
  • [Cites] Biochemistry (Mosc). 2006 Apr;71(4):354-60 [16615854.001]
  • [Cites] Electrophoresis. 2006 Apr;27(8):1641-50 [16550499.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1641-6 [16985025.001]
  • [Cites] Curr Treat Options Oncol. 2006 Nov;7(6):479-89 [17032560.001]
  • [Cites] Pancreas. 2007 Mar;34(2):205-14 [17312459.001]
  • [Cites] Histochem Cell Biol. 1995 Feb;103(2):135-45 [7634153.001]
  • (PMID = 18257091.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS43284; United States / NINDS NIH HHS / NS / R01 NS049514-03; United States / NINDS NIH HHS / NS / NS049514-03; United States / NINDS NIH HHS / NS / R01 NS38195; United States / NINDS NIH HHS / NS / R21 NS077236; United States / NHLBI NIH HHS / HL / R01 HL051614; United States / NHLBI NIH HHS / HL / 2R01 HL51614; United States / NINDS NIH HHS / NS / R01 NS049514; United States / NINDS NIH HHS / NS / R01 NS038195
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apolipoprotein A-I; 0 / Biomarkers, Tumor; 0 / Haptoglobins; 0 / Nerve Growth Factors; 0 / Prealbumin; 0 / S100 Calcium Binding Protein beta Subunit; 0 / S100 Proteins; 0 / Transferrin
  • [Other-IDs] NLM/ NIHMS82107; NLM/ PMC2775530
  •  go-up   go-down


55. Harita S, Mizuta A, Kuyama S, Kikuchi T: Long-term survival following concurrent chemoradiotherapy in patients with non-small-cell lung cancer with concomitant brain metastases only. Int J Clin Oncol; 2005 Feb;10(1):63-8
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival following concurrent chemoradiotherapy in patients with non-small-cell lung cancer with concomitant brain metastases only.
  • We report two patients with non-small-cell lung cancer (NSCLC) with concomitant metastases to the brain only who received chemotherapy with concurrent radiotherapy for the thoracic disease and brain disease, resulting in long-term survival.
  • One patient was a 56-year-old woman who was diagnosed as having adenocarcinoma and showed T2N1 thoracic disease; the other patient was a 57-year-old man diagnosed with squamous cell carcinoma who had T1N3 thoracic disease.
  • Both patients demonstrated multiple metastases to the brain only.
  • Whole-brain irradiation (2 Gy/day; total, 36 Gy) and thoracic irradiation (2 Gy/day; total, 60 Gy) were started on days 1 and 29, respectively.
  • The concurrent chemoradiation therapy resulted in complete regression of the brain disease in both patients.
  • Brain disease relapsed in the female patient, but it is being controlled by the administration of gefitinib.
  • She has survived for 53 months since the start of treatment, without new metastatic lesions or relapse of the thoracic lesions.
  • The male patient has survived for 37 months without new metastatic lesions or relapses.
  • Concurrent chemoradiotherapy in which radiotherapy is applied to both the brain and thoracic lesions may be effective for patients with NSCLC with metastases to the brain only.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Brain Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / radiotherapy. Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy


56. Rettenmaier NB, Epstein HD, Oi S, Robinson PA, Goldstein BH: Cerebral nocardia masquerading as metastatic CNS disease in an endometrial cancer patient. Eur J Gynaecol Oncol; 2009;30(1):90-2
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebral nocardia masquerading as metastatic CNS disease in an endometrial cancer patient.
  • We present the case of a 61-year-old woman previously treated for endometrial carcinoma, who three years later developed metastatic pulmonary disease and received systemic chemotherapy.
  • After five months, she developed a large right posterior lobe lesion, suspicious for metastatic CNS disease.
  • However, following neurosurgical resection of the lesion and infectious disease consultation, a diagnosis of nocardia was made.
  • [MeSH-major] Adenocarcinoma / secondary. Brain Abscess / diagnosis. Endometrial Neoplasms / pathology. Lung Neoplasms / secondary. Nocardia Infections / diagnosis

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19317267.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


57. Boutemy M, Mispelaere D, Krzisch C, Jounieaux V: [Evaluation of combined chemotherapy with vinorelbine, ifosfamide and cisplatin in the treatment of metastatic non-small cell bronchial carcinoma]. Rev Mal Respir; 2005 Jun;22(3):413-9
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of combined chemotherapy with vinorelbine, ifosfamide and cisplatin in the treatment of metastatic non-small cell bronchial carcinoma].
  • Non small cell lung cancer (NSCLC) represents 80% of bronchial carcinoma of which 40-50% are mefastatic at the time of diagnosis.
  • CONCLUSION: Treatment of stage IV NSCLC with NIP chemotherapy is effective and improves the survival of these patients independently of other prognostic factors such as age, the presence of cerebral metastases, performance status, histological type, the number of metastatic sites or the serum LOH level.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adult. Aged. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Carcinoma, Bronchogenic / drug therapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Cisplatin / administration & dosage. Cisplatin / adverse effects. Cohort Studies. Female. Gastrointestinal Diseases / chemically induced. Hematologic Diseases / chemically induced. Humans. Ifosfamide / administration & dosage. Ifosfamide / adverse effects. Life Tables. Male. Middle Aged. Retrospective Studies. Smoking / adverse effects. Survival Analysis. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / adverse effects. Vinblastine / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16227927.001).
  • [ISSN] 0761-8425
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


58. Hu H, Yao HT, Zhang WP, Zhang L, Ding W, Zhang SH, Chen Z, Wei EQ: Increased expression of aquaporin-4 in human traumatic brain injury and brain tumors. J Zhejiang Univ Sci B; 2005 Jan;6(1):33-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of aquaporin-4 in human traumatic brain injury and brain tumors.
  • OBJECTIVE: To characterize the expression of aquaporin-4 (AQP4), one of the aquaporins (AQPs), in human brain specimens from patients with traumatic brain injury or brain tumors.
  • METHODS: Nineteen human brain specimens were obtained from the patients with traumatic brain injury, brain tumors, benign meningioma or early stage hemorrhagic stroke.
  • MRI or CT imaging was used to assess brain edema.
  • AQP4 immunoreactivity was strong around astrocytomas, ganglioglioma and metastatic adenocarcinoma.
  • However, AQP4 immunoreactivity was only found in the centers of astrocytomas and ganglioglioma, but not in metastatic adenocarcinoma derived from lung.
  • CONCLUSION: AQP4 expression increases in human brains after traumatic brain injury, within brain-derived tumors, and around brain tumors.
  • [MeSH-major] Aquaporins / metabolism. Brain Edema / metabolism. Brain Edema / pathology. Brain Injuries / metabolism. Brain Injuries / pathology. Brain Neoplasms / metabolism. Brain Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2000 Feb;6(2):159-63 [10655103.001]
  • [Cites] Brain Res Mol Brain Res. 2000 May 31;78(1-2):131-7 [10891592.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2002 Feb;72(2):262-5 [11796780.001]
  • [Cites] Brain Res Brain Res Rev. 2002 Jun;39(1):55-73 [12086708.001]
  • [Cites] J Anat. 2002 Jun;200(6):617-27 [12162729.001]
  • [Cites] J Neurosurg. 2003 Mar;98(3):565-9 [12650429.001]
  • [Cites] Acta Neuropathol. 2003 Aug;106(2):121-4 [12715185.001]
  • [Cites] J Biol Chem. 1988 Oct 25;263(30):15634-42 [3049610.001]
  • [Cites] J Neurosci. 1997 Jan 1;17(1):171-80 [8987746.001]
  • [Cites] J Biol Chem. 1997 Jun 27;272(26):16140-6 [9195910.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11981-6 [9751776.001]
  • (PMID = 15593389.001).
  • [ISSN] 1673-1581
  • [Journal-full-title] Journal of Zhejiang University. Science. B
  • [ISO-abbreviation] J Zhejiang Univ Sci B
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / AQP4 protein, human; 0 / Aquaporin 4; 0 / Aquaporins; 0 / Biomarkers
  • [Other-IDs] NLM/ PMC1390756
  •  go-up   go-down


59. Delgado-López PD, Martín-Velasco V, Castilla-Díez JM, Fernández-Arconada O, Corrales-García EM, Galacho-Harnero A, Rodríguez-Salazar A, Pérez-Mies B: Metastatic meningioma to the eleventh dorsal vertebral body: total en bloc spondylectomy. Case report and review of the literature. Neurocirugia (Astur); 2006 Jun;17(3):240-9
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic meningioma to the eleventh dorsal vertebral body: total en bloc spondylectomy. Case report and review of the literature.
  • Lung and intraabdominal organs are most frequently affected.
  • To our knowledge, this is the first description of a total en bloc spondylectomy through a posterior approach for the treatment of an intraosseous metastatic meningioma to the eleventh dorsal vertebra.
  • The pathological specimen was identified as adenocarcinoma and he initiated chemotherapy.
  • Advice from a second pathologist was seeked, who suggested the diagnosis of intraosseous meningioma.
  • In May 2004 the patient was admitted to our department and a new transpedicular biopsy confirmed the diagnosis.
  • Such score correlates with the chance of metastatizing: more than 40% in malignant meningiomas compared to 3.8% of brain tumors overall.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16855782.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


60. Ota S, Tsuchiya K, Anno M, Akiyamat H: [An autopsy case of miliary brain metastases]. No To Shinkei; 2006 Feb;58(2):161-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An autopsy case of miliary brain metastases].
  • A 57-year-old man was admitted to our hospital with a diagnosis of psychiatric emergency.
  • Brain CT was also normal, therefore it was difficult to make a diagnosis.
  • But, we could clinically diagnose him as having pulmonary adenocarcinoma with numerous metastatic nodules of the brain.
  • Because miliary lesions in the cerebral hemispheres, brainstem and cerebellum were disclosed on brain MRI.
  • Furthermore, chest CT revealed the lung tumor in the left S8 area.
  • There was neither edema in the surrounding region of metastatic nodules nor mass effect on all MR images.
  • Spinal MRI showed no metastatic lesions.
  • The brain weighed 1,575 g.
  • Neuropathological findings revealed diffuse miliary brain metastases located in all parts of the brain, except for the medulla oblongata.
  • Histological examination disclosed multiple metastases from a well-differentiated adenocarcinoma with a predominant tubular pattern.
  • There was neither edema nor glial reaction in the surrounding area of metastatic lesions.
  • [MeSH-major] Adenocarcinoma / pathology. Brain Neoplasms / pathology. Brain Neoplasms / secondary. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16519114.001).
  • [ISSN] 0006-8969
  • [Journal-full-title] Nō to shinkei = Brain and nerve
  • [ISO-abbreviation] No To Shinkei
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


61. Karim A, Fowler M, Jones L, Patwardhan R, Vannemreddy P, Mccarthy K, Nanda A: Cyclooxygenase-2 expression in brain metastases. Anticancer Res; 2005 Jul-Aug;25(4):2969-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclooxygenase-2 expression in brain metastases.
  • BACKGROUND: Elevated Cyclooxygenase-2 (COX-2) expression is thought to increase metastatic potential of many tumors.
  • We evaluated whether: (i) the degree of COX-2 expression correlated with either metastatic tumor type or with the presence of necrosis and whether (ii) radiation-resistant tumors (renal cell and melanoma) had higher expression of COX-2 than did relatively radiation-sensitive tumors (breast and lung).
  • MATERIALS AND METHODS: Specimens from sixteen patients who underwent resection of brain metastases were analyzed for COX-2 expression using a COX-2 antibody-based immunoassay.
  • Specimens consisted of brain metastases from lung tumors, breast adenocarcinomas, melanomas and renal cell carcinomas.
  • RESULTS: Ten of sixteen brain metastasis specimens had ten percent or less Cox-2 immunostaining.
  • Statistical analyses showed no correlation between Cox-2 immunostaining and metastatic tumor type or between Cox-2 immunostaining and necrosis in this study.
  • CONCLUSION: Cox-2 is not consistently expressed in metastases to the brain.
  • The degree of Cox-2 expression does not correlate with metastatic tumor type or with the presence of necrosis.
  • [MeSH-major] Brain Neoplasms / enzymology. Brain Neoplasms / secondary. Prostaglandin-Endoperoxide Synthases / biosynthesis
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / secondary. Adult. Aged. Breast Neoplasms / enzymology. Breast Neoplasms / pathology. Carcinoma, Ductal / enzymology. Carcinoma, Ductal / secondary. Carcinoma, Renal Cell / enzymology. Carcinoma, Renal Cell / secondary. Cyclooxygenase 2. Female. Humans. Kidney Neoplasms / enzymology. Kidney Neoplasms / pathology. Lung Neoplasms / enzymology. Lung Neoplasms / pathology. Male. Melanoma / enzymology. Melanoma / secondary. Membrane Proteins. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16080553.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Membrane Proteins; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  •  go-up   go-down


62. Barajas RF, Chang JS, Sneed PK, Segal MR, McDermott MW, Cha S: Distinguishing recurrent intra-axial metastatic tumor from radiation necrosis following gamma knife radiosurgery using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. AJNR Am J Neuroradiol; 2009 Feb;30(2):367-72
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinguishing recurrent intra-axial metastatic tumor from radiation necrosis following gamma knife radiosurgery using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging.
  • BACKGROUND AND PURPOSE: MR image-guided gamma knife radiosurgery is often used to treat intra-axial metastatic neoplasms.
  • Following treatment, it is often difficult to determine whether a progressively enhancing lesion is due to metastatic tumor recurrence or radiation necrosis.
  • The purpose of our study was to determine whether relative cerebral blood volume (rCBV), relative peak height (rPH), and percentage of signal-intensity recovery (PSR) derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging can distinguish recurrent metastatic tumor from radiation necrosis.
  • MATERIALS AND METHODS: Twenty-seven patients with systemic cancer underwent gamma knife radiosurgery for metastatic lesions of the brain and subsequently developed enlarging regions of enhancement within the radiation field.
  • Subsequent surgical resection or clinicoradiologic follow-up established a diagnosis of recurrent metastatic tumor or radiation necrosis.
  • RESULTS: The mean, minimum, and maximum PSR values were significantly lower (P < .01) in cases of recurrent metastatic tumor.
  • The mean and maximum rCBV and rPH values were significantly higher (P < .02) in the recurrent metastatic tumor group.
  • CONCLUSIONS: The findings of our study suggest that perfusion MR imaging may be used to differentiate recurrent intra-axial metastatic tumor from gamma knife-induced radiation necrosis.
  • [MeSH-major] Brain Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Magnetic Resonance Imaging / methods. Neoplasm Recurrence, Local / diagnosis. Postoperative Complications / diagnosis. Radiosurgery / adverse effects
  • [MeSH-minor] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Breast Neoplasms / pathology. Carcinoma, Non-Small-Cell Lung / secondary. Carcinoma, Non-Small-Cell Lung / surgery. Carcinoma, Renal Cell / secondary. Carcinoma, Renal Cell / surgery. Contrast Media. Diagnosis, Differential. Female. Humans. Kidney Neoplasms / pathology. Male. Middle Aged. Necrosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19022867.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS045013; United States / NCRR NIH HHS / RR / TL1 RR024129-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


63. Goldfarb Y, Benish M, Rosenne E, Melamed R, Levi B, Glasner A, Ben-Eliyahu S: CpG-C oligodeoxynucleotides limit the deleterious effects of beta-adrenoceptor stimulation on NK cytotoxicity and metastatic dissemination. J Immunother; 2009 Apr;32(3):280-91
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CpG-C oligodeoxynucleotides limit the deleterious effects of beta-adrenoceptor stimulation on NK cytotoxicity and metastatic dissemination.
  • Suppression of natural killer (NK) cell activity is common after stress, has been reported to predict malignant recurrence in cancer patients, and was shown to underlie metastatic dissemination in animal models.
  • In the current study using Fisher 344 rats, we examined the prophylactic use of different regimens of type-C CpG oligodeoxynucleotides (CpG-C ODN) on NK activity and metastatic dissemination in the context of pharmacologic stress (using metaproterenol for beta-adrenoceptor stimulation).
  • A bolus of CpG-C ODN (330 microg/kg, intraperitoneally) 24 hours before metaproterenol-challenge was most effective at reducing lung tumor retention of an experimental syngeneic mammary adenocarcinoma (MADB106), although having no observable side effects.
  • Depletion of NK cells revealed their key role in improving baseline levels of resistance to metastatic dissemination after CpG-C ODN administration.
  • Overall, prophylactic CpG-C ODN treatment can improve immunocompetence and potentially reduce metastatic dissemination, especially in clinical settings characterized by enhanced sympathetic stress responses.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1999 Nov 1;59(21):5429-32 [10554011.001]
  • [Cites] J Immunol. 2008 Mar 15;180(6):4067-74 [18322216.001]
  • [Cites] J Exp Med. 1989 Apr 1;169(4):1373-89 [2466943.001]
  • [Cites] J Clin Lab Anal. 1990;4(4):274-82 [2391582.001]
  • [Cites] Eur J Clin Invest. 1992 Oct;22 Suppl 1:30-6 [1333965.001]
  • [Cites] Ann Surg Oncol. 2008 Jul;15(7):2042-52 [18398660.001]
  • [Cites] Breast Cancer Res Treat. 2000 Apr;60(3):227-34 [10930110.001]
  • [Cites] Pharmacol Rev. 2000 Dec;52(4):595-638 [11121511.001]
  • [Cites] Neuroimmunomodulation. 2000;8(3):154-64 [11124582.001]
  • [Cites] Nature. 2000 Dec 7;408(6813):740-5 [11130078.001]
  • [Cites] Eur J Immunol. 2001 Jun;31(6):1900-9 [11433387.001]
  • [Cites] Cancer Res. 2001 Jul 15;61(14):5523-8 [11454702.001]
  • [Cites] J Immunol. 2001 Aug 1;167(3):1141-4 [11466327.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9237-42 [11470918.001]
  • [Cites] Antisense Nucleic Acid Drug Dev. 2001 Oct;11(5):333-40 [11763350.001]
  • [Cites] Annu Rev Immunol. 2002;20:709-60 [11861616.001]
  • [Cites] Brain Behav Immun. 2003 Feb;17 Suppl 1:S27-36 [12615183.001]
  • [Cites] Am J Respir Cell Mol Biol. 2003 May;28(5):541-5 [12707008.001]
  • [Cites] J Leukoc Biol. 2003 Jun;73(6):781-92 [12773511.001]
  • [Cites] J Am Coll Surg. 2003 Aug;197(2):254-60 [12892809.001]
  • [Cites] Dig Surg. 2003;20(5):445-51 [12900537.001]
  • [Cites] Ann Surg Oncol. 2003 Oct;10(8):972-92 [14527919.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10116-21 [15218108.001]
  • [Cites] J Invest Dermatol. 2004 Aug;123(2):395-402 [15245441.001]
  • [Cites] J Immunol. 2004 Aug 1;173(3):1647-57 [15265893.001]
  • [Cites] Arch Int Pharmacodyn Ther. 1976 Sep;223(1):71-87 [999404.001]
  • [Cites] J Immunol Methods. 1981;42(3):305-18 [7026679.001]
  • [Cites] Nat Med. 1996 Apr;2(4):457-60 [8597957.001]
  • [Cites] J Immunol. 1996 Sep 1;157(5):2116-22 [8757335.001]
  • [Cites] Br J Cancer. 1996 Dec;74(12):1900-7 [8980388.001]
  • [Cites] J Immunol. 1998 Apr 1;160(7):3251-8 [9531281.001]
  • [Cites] Nat Med. 1999 Apr;5(4):405-11 [10202929.001]
  • [Cites] J Immunol. 2005 Jan 15;174(2):727-34 [15634892.001]
  • [Cites] Brain Behav Immun. 2005 Mar;19(2):114-26 [15664784.001]
  • [Cites] DNA Cell Biol. 2005 Feb;24(2):63-72 [15699627.001]
  • [Cites] Eur J Cancer. 2005 Mar;41(4):508-15 [15737554.001]
  • [Cites] J Clin Invest. 2005 Mar;115(3):739-46 [15696196.001]
  • [Cites] Curr Pharm Des. 2005;11(22):2889-907 [16101444.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7105-13 [16192594.001]
  • [Cites] Eur J Immunol. 2006 Apr;36(4):961-7 [16525994.001]
  • [Cites] Nat Rev Drug Discov. 2006 Jun;5(6):471-84 [16763660.001]
  • [Cites] J Control Release. 2006 Oct 10;115(2):226-33 [16996162.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3851-8 [16873676.001]
  • [Cites] Vet Immunol Immunopathol. 2007 Jan 15;115(1-2):24-34 [17067685.001]
  • [Cites] Brain Behav Immun. 2007 May;21(4):395-408 [17240115.001]
  • [Cites] Brain Behav Immun. 2007 May;21(4):503-13 [17293081.001]
  • [Cites] Immunol Res. 2007;39(1-3):15-21 [17917052.001]
  • [Cites] Vaccine. 2007 Nov 28;25(49):8241-56 [17980936.001]
  • [Cites] J Immunother. 2007 Nov-Dec;30(8):789-97 [18049330.001]
  • [Cites] Breast Cancer Res Treat. 2008 Jan;107(2):211-23 [17431763.001]
  • [Cites] J Neuroimmunol. 2008 Jan;193(1-2):113-9 [18037507.001]
  • [Cites] J Immunol. 1985 Apr;134(4):2783-9 [3871818.001]
  • (PMID = 19242372.001).
  • [ISSN] 1537-4513
  • [Journal-full-title] Journal of immunotherapy (Hagerstown, Md. : 1997)
  • [ISO-abbreviation] J. Immunother.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA125456; United States / NCI NIH HHS / CA / CA125456-01A1; United States / NCI NIH HHS / CA / R01 CA125456-02; United States / NCI NIH HHS / CA / CA125456-02; United States / NCI NIH HHS / CA / R01 CA125456; United States / NCI NIH HHS / CA / R01 CA125456-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / CPG-oligonucleotide; 0 / Oligodeoxyribonucleotides; 0 / Receptors, Adrenergic, beta; 53QOG569E0 / Metaproterenol
  • [Other-IDs] NLM/ NIHMS126415; NLM/ PMC2738855
  •  go-up   go-down


64. Barthomeuf C, Lim S, Iranshahi M, Chollet P: Umbelliprenin from Ferula szowitsiana inhibits the growth of human M4Beu metastatic pigmented malignant melanoma cells through cell-cycle arrest in G1 and induction of caspase-dependent apoptosis. Phytomedicine; 2008 Jan;15(1-2):103-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Umbelliprenin from Ferula szowitsiana inhibits the growth of human M4Beu metastatic pigmented malignant melanoma cells through cell-cycle arrest in G1 and induction of caspase-dependent apoptosis.
  • Metastatic malignant melanoma have a bad prognosis (median survival: 6-8 months) mainly due to the development of lung, hepatic and brain metastases.
  • We have observed that the cell susceptibility to umbelliprenin decreases in the order M4Beu (metastatic pigmented malignant melanoma)>A549 (nonsmall cell lung carcinoma) approximately PC3 (androgen-resistant prostate carcinoma)>PA1 (ovary teratocarcinoma)>human primary fibroblasts approximately MCF7 (breast adenocarcinoma)>DLD1 (colon adenocarcinoma).
  • As M4Beu cell proliferation is more potently inhibited by umbelliprenin (IC50 12.3 microM) than by the citrus coumarin auraptene (7-geranyloxycoumarin, IC50 17.1 microM) previously reported capable of inhibiting the prevalence of lung metastasis in mice bearing B16BL6 murine melanoma, our data suggest that umbelliprenin orally administered and foods and folk medicines containing this coumarin, may afford protection against the development and early recurrence of malignant melanoma.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17689942.001).
  • [ISSN] 0944-7113
  • [Journal-full-title] Phytomedicine : international journal of phytotherapy and phytopharmacology
  • [ISO-abbreviation] Phytomedicine
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Coumarins; 0 / Umbelliferones; 495-02-3 / aurapten; EC 3.4.22.- / Caspases; MSD8N8A1LQ / umbelliprenin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


65. Miyazaki T, Tagawa T, Nakamura A, Yamasaki N, Hashizume S, Matsumoto K, Taguchi T, Morino S, Nagayasu T: [Surgical treatment for stage IV lung cancer]. Kyobu Geka; 2006 Jan;59(1):36-40
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment for stage IV lung cancer].
  • OBJECTIVE: To find out the optimal surgical indication in stage IV lung cancer patients, we evaluated them retrospectively.
  • The most common histological type was adenocarcinoma (67.7%).
  • The metastatic lesions were lung (33.9%), brain (24.2%), liver, bone, adrenal gland and so on.
  • The overall survival rate of stage IV lung cancer was 10.4% at 5-year.
  • Five-year survival for patients with lung or brain metastasis who had no lymph node metastasis were significantly more superior than those with lymph node metastasis (p=0.0389, 0.0021).
  • Two were lung and the others were brain and adrenal gland metastasis without lymph node metastasis.
  • CONCLUSION: Stage IV lung cancer with lung or brain or adrenal gland metastasis without lymph node metastasis should be resected.
  • [MeSH-major] Lung Neoplasms / pathology. Lung Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Brain Neoplasms / mortality. Brain Neoplasms / secondary. Female. Humans. Male. Middle Aged. Neoplasm Staging / mortality. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16440683.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


66. Chen CH, Lai JM, Chou TY, Chen CY, Su LJ, Lee YC, Cheng TS, Hong YR, Chou CK, Whang-Peng J, Wu YC, Huang CY: VEGFA upregulates FLJ10540 and modulates migration and invasion of lung cancer via PI3K/AKT pathway. PLoS One; 2009;4(4):e5052
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] VEGFA upregulates FLJ10540 and modulates migration and invasion of lung cancer via PI3K/AKT pathway.
  • BACKGROUND: Lung adenocarcinoma is the leading cause of cancer-related deaths among both men and women in the world.
  • Despite recent advances in diagnosis and treatment, the mortality rates with an overall 5-year survival of only 15%.
  • Although several well-known markers correlated with poor/metastasis prognosis in lung adenocarcinoma patients by immunohistochemistry was reported, the molecular mechanisms of lung adenocarcinoma development are still not clear.
  • To explore novel molecular markers and their signaling pathways will be crucial for aiding in treatment of lung adenocarcinoma patients.
  • METHODOLOGY/PRINCIPAL FINDINGS: To identify novel lung adenocarcinoma-associated /metastasis genes and to clarify the underlying molecular mechanisms of these targets in lung cancer progression, we created a bioinformatics scheme consisting of integrating three gene expression profile datasets, including pairwise lung adenocarcinoma, secondary metastatic tumors vs. benign tumors, and a series of invasive cell lines.
  • Among the novel targets identified, FLJ10540 was overexpressed in lung cancer tissues and is associated with cell migration and invasion.
  • Lung adenocarcinoma array profiles and tissue microarray IHC staining data showed that FLJ10540 and VEGF-A, as well as FLJ10540 and phospho-AKT exhibit positive correlations, respectively.
  • Stimulation of lung cancer cells with VEGF-A results in an increase in FLJ10540 protein expression and enhances complex formation with PI3K.
  • CONCLUSIONS/SIGNIFICANCE: This finding set the stage for further testing of FLJ10540 as a new therapeutic target for treating lung cancer and may contribute to the development of new therapeutic strategies that are able to block the PI3K/AKT pathway in lung cancer cells.
  • [MeSH-major] Adenocarcinoma / pathology. Cell Cycle Proteins / physiology. Lung Neoplasms / pathology. Neoplasm Invasiveness. Neoplasm Metastasis. Nuclear Proteins / physiology. Phosphatidylinositol 3-Kinases / metabolism. Proto-Oncogene Proteins c-akt / metabolism. Up-Regulation / physiology. Vascular Endothelial Growth Factor A / physiology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Cell. 2002 Apr;1(3):219-27 [12086857.001]
  • [Cites] Nature. 1999 Dec 2;402(6761):483-7 [10591207.001]
  • [Cites] Nat Rev Cancer. 2003 May;3(5):362-74 [12724734.001]
  • [Cites] J Pathol. 2003 Jul;200(3):336-47 [12845630.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Jul;12(7):660-4 [12869408.001]
  • [Cites] Biochem Soc Trans. 2003 Dec;31(Pt 6):1171-7 [14641020.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2004 Feb;24(2):294-300 [14656735.001]
  • [Cites] Mol Ther. 2004 Apr;9(4):510-8 [15093181.001]
  • [Cites] Nat Rev Cancer. 2004 Jun;4(6):423-36 [15170445.001]
  • [Cites] J Biol Chem. 2004 Jul 30;279(31):32592-602 [15145941.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6865-71 [15501963.001]
  • [Cites] Apoptosis. 2004 Nov;9(6):667-76 [15505410.001]
  • [Cites] Cancer Metastasis Rev. 1996 Dec;15(4):507-25 [9034607.001]
  • [Cites] Int J Cancer. 1997 Feb 20;74(1):64-8 [9036871.001]
  • [Cites] Am J Respir Cell Mol Biol. 1997 Sep;17(3):353-60 [9308922.001]
  • [Cites] Br J Cancer. 1997;76(8):1041-5 [9376264.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):589-93 [11212254.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):3986-97 [11358816.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5223-30 [11431363.001]
  • [Cites] Langenbecks Arch Surg. 2001 Jul;386(4):293-301 [11466572.001]
  • [Cites] FASEB J. 2001 Sep;15(11):1953-62 [11532975.001]
  • [Cites] J Natl Cancer Inst. 2001 Sep 19;93(18):1392-400 [11562390.001]
  • [Cites] Clin Cancer Res. 2001 Nov;7(11):3410-5 [11705856.001]
  • [Cites] Br J Cancer. 2002 Feb 12;86(4):558-63 [11870537.001]
  • [Cites] Science. 2002 May 31;296(5573):1655-7 [12040186.001]
  • [Cites] J Biol Chem. 1997 Dec 19;272(51):32521-7 [9405464.001]
  • [Cites] Clin Cancer Res. 1998 Jun;4(6):1483-7 [9626466.001]
  • [Cites] J Biol Chem. 1999 Apr 9;274(15):10002-7 [10187776.001]
  • [Cites] Am J Respir Crit Care Med. 1999 Oct;160(4):1269-73 [10508818.001]
  • [Cites] Lung. 2004;182(3):151-62 [15526754.001]
  • [Cites] Am J Respir Crit Care Med. 2004 Nov 15;170(10):1088-94 [15317667.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Dev Cell. 2005 Oct;9(4):477-88 [16198290.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Dec 16;338(2):830-8 [16256070.001]
  • [Cites] Oncogene. 2005 Nov 14;24(50):7443-54 [16288291.001]
  • [Cites] Mol Cell. 2005 Nov 23;20(4):539-50 [16307918.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):46-51 [16397214.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):306-14 [16330671.001]
  • [Cites] Oncogene. 2006 Jan 19;25(3):480-6 [16170351.001]
  • [Cites] Genomics. 2006 Feb;87(2):243-53 [16406728.001]
  • [Cites] Oncogene. 2006 Jan 26;25(4):609-21 [16158046.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1354-62 [16452189.001]
  • [Cites] Cancer Lett. 2006 Apr 8;235(1):53-9 [15899546.001]
  • [Cites] Cell Cycle. 2006 Mar;5(6):603-5 [16582622.001]
  • [Cites] J Biol Chem. 2006 Aug 11;281(32):23285-95 [16787925.001]
  • [Cites] Mol Biol Cell. 2006 Sep;17(9):3881-96 [16790497.001]
  • [Cites] Curr Opin Investig Drugs. 2007 Feb;8(2):140-9 [17328230.001]
  • [Cites] J Biol Chem. 2007 Mar 16;282(11):7758-69 [17178724.001]
  • [Cites] Oncogene. 2007 Jun 21;26(29):4272-83 [17237822.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Aug;63(2):172-82 [17540577.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Behav Brain Res. 2002 Nov 15;136(2):489-501 [12429412.001]
  • (PMID = 19337377.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Cep55 protein, human; 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / Vascular Endothelial Growth Factor A; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  • [Other-IDs] NLM/ PMC2659802
  •  go-up   go-down


67. Abe T, Hayashi M, Tsutsui N, Ito K, Haraguchi M: [Two cases of meningeal carcinomatosis during gefitinib therapy for non-small cell lung cancer]. Nihon Kokyuki Gakkai Zasshi; 2006 Feb;44(2):144-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of meningeal carcinomatosis during gefitinib therapy for non-small cell lung cancer].
  • "Case 1" A 56-year-old woman who suffered from postoperative recurrent non-small cell lung cancer received gefitinib therapy.
  • "Case 2" A 46-year-old man with stage IV non-small cell lung cancer started gefitinib therapy after chemotherapy.
  • The pulmonary lesions markedly improved responding to gefitinib therapy, however, approximately 6 months after the therapy was begun, multiple brain metastasis and meningeal carcinomatosis were detected.
  • Approximately 4 months after the diagnosis of meningeal carcinomatosis, he died of disease progression and disturbance of consciousness.
  • It has been reported that the central nervous system is a frequent metastatic site of non-small cell lung cancer in patients treated with gefitinib.
  • We should consider the possibility of metastatic central nervous system disease, even in patients in whom gefitinib therapy is apparently successful.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / etiology. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Meningeal Neoplasms / etiology. Quinazolines / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Disease Progression. Fatal Outcome. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17228810.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


68. Matsuoka T, Morikage N, Kuga T, Nakayama T, Fujii Y: [A case of complete response in a primary lesion treated by gefitinib for two years after surgery of brain metastasis from lung cancer]. Gan To Kagaku Ryoho; 2006 Apr;33(4):497-500
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of complete response in a primary lesion treated by gefitinib for two years after surgery of brain metastasis from lung cancer].
  • Under a diagnosis of cerebellar tumor and right lung tumor, she underwent a resection of cerebellar tumor on August 7, 2001.
  • The histopathological diagnosis was "metastatic adenocarcinoma".
  • Lung cancer was doubted as for the origin, however, she did not want further examination.
  • [MeSH-major] Adenocarcinoma, Papillary / drug therapy. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cerebellar Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16612160.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; 5V9KLZ54CY / Vinblastine; BG3F62OND5 / Carboplatin; Q6C979R91Y / vinorelbine; S65743JHBS / gefitinib
  •  go-up   go-down


69. Miyahara H, Itou H, Sekine A, Taniyama D, Katsui T, Tanaka W, Satou R, Kurihara A, Satou Y, Sakamaki F: [A case of adult T-cell leukemia/lymphoma with primary lung cancer]. Nihon Kokyuki Gakkai Zasshi; 2009 Apr;47(4):342-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of adult T-cell leukemia/lymphoma with primary lung cancer].
  • Cranial MRI showed an enlarged mass 5cm in diameter with intracranial invasion and metastatic brain tumors.
  • Furthermore, since we noted multiple cervical lymphadenopathy, we performed an additional biopsy, which showed poorly-differentiated adenocarcinoma.
  • We diagnosed stage IV primary lung cancer and started chemotherapy.
  • Autopsy showed ATLL and extensive lung cancer with multiple metastases.
  • There was invasion of ATLL in systemic lymph nodes, which coincided with invasion of adenocarcinoma.
  • CONCLUSION: We encountered a rare case of ATLL and primary lung cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Leukemia-Lymphoma, Adult T-Cell / pathology. Lung Neoplasms / pathology. Neoplasms, Multiple Primary

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19455967.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


70. Gontier E, Vaylet F, Bonardel G, Mantzarides M, Salles Y, Guigay J, Foehrenbach H, L'Her P: [18-FDG positon emission tomography and distal metastasis from lung cancer]. Rev Pneumol Clin; 2005 Sep;61(4 Pt 1):248-57
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [18-FDG positon emission tomography and distal metastasis from lung cancer].
  • We report the cases of three patients with non-small-cell lung cancer who developed secondary distal localizations beyond the acquisition field of "whole body" FDG-PET.
  • Lung cancer is known to favor hematogenic dissemination, raising the possibility of early distal metastasis.
  • Furthermore, the diagnostic yield of this type of examination may be low since it can be estimated that about 1% of patients will develop isolated distal metastases (3 out of 293 patients in our series initially treated for non-metastatic non-small-cell lung cancer).
  • In the current context of technical availability, systematic inclusion of the lower limbs in the PET scan acquisition field would not appear warranted for the initial work-up of patients with non-small-cell lung cancer.
  • However, clinicians must be aware that distal metastases (brain, lower limbs) may not be detected.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Fluorodeoxyglucose F18. Lung Neoplasms / pathology. Positron-Emission Tomography. Radiopharmaceuticals. Whole Body Imaging
  • [MeSH-minor] Adenocarcinoma / secondary. Aged. Aged, 80 and over. Bone Neoplasms / secondary. Carcinoma, Squamous Cell / secondary. Female. Femur / pathology. Humans. Male. Middle Aged. Muscle Neoplasms / secondary. Retrospective Studies. Tibia / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16208188.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


71. Noguchi T, Nakayama E, Yasuda J, Terada Y: [A case of meningeal carcinomatosis from lung cancer successfully treated with aggressive multimodal therapy]. Nihon Kokyuki Gakkai Zasshi; 2007 Mar;45(3):267-71
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of meningeal carcinomatosis from lung cancer successfully treated with aggressive multimodal therapy].
  • A 44-year-old man was admitted to our hospital because of brain metastasis and intrapulmonary exacerbation of lung adenocarcinoma.
  • Whole-brain and whole-marrow radiation along with systemic chemotherapy gave a marked improvement in the symptoms and in the metastatic shadow on the chest CT scan.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow / radiation effects. Cranial Irradiation. Lung Neoplasms / pathology. Meningeal Neoplasms / drug therapy. Meningeal Neoplasms / secondary

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17419441.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


72. Rojiani MV, Alidina J, Esposito N, Rojiani AM: Expression of MMP-2 correlates with increased angiogenesis in CNS metastasis of lung carcinoma. Int J Clin Exp Pathol; 2010;3(8):775-81
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of MMP-2 correlates with increased angiogenesis in CNS metastasis of lung carcinoma.
  • Matrix metalloproteinases (MMP) have been implicated in increased invasive and metastatic potential of tumors, possibly via interactions with the extracellular matrix and angiogenesis.
  • This study investigates the relationship between MMP-2 immunoexpression and angiogenesis in a series of lung carcinomas metastatic to the central nervous system (CNS).
  • Twenty eight metastatic carcinoma cases with adequate brain-tumor interface were identified from the archives at the Moffitt Cancer Center.
  • Mean microvessel area (MMVA) and mean microvessel number (MMVN) were assessed within areas of brain-tumor interface and within the tumor and expressed as a ratio relative to the tumor.
  • Sixteen (57.14%) metastatic tumors were strongly immunoreac-tive for MMP-2, while 12 (42.86%) were negative.
  • MMP-2 expression thus appears to confer enhanced vascular proliferation particularly at the brain-tumor interface which would support the contention of enhanced capability of growth and invasion within the CNS, possibly modulated by MMP2.
  • [MeSH-major] Adenocarcinoma / blood supply. Brain Neoplasms / blood supply. Lung Neoplasms / blood supply. Matrix Metalloproteinase 2 / metabolism. Neovascularization, Pathologic / enzymology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Prostate. 2000 Jan;42(1):18-25 [10579795.001]
  • [Cites] Pediatr Nephrol. 1993 Feb;7(1):96-104 [8439492.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):3884-9 [10760260.001]
  • [Cites] Nat Cell Biol. 2000 Oct;2(10):737-44 [11025665.001]
  • [Cites] Curr Opin Cell Biol. 2001 Oct;13(5):534-40 [11544020.001]
  • [Cites] Science. 2002 Jun 7;296(5574):1883-6 [11976409.001]
  • [Cites] Cancer. 2002 Nov 1;95(9):1902-10 [12404284.001]
  • [Cites] Cell. 1985 Sep;42(2):469-77 [2411423.001]
  • [Cites] Science. 1987 Jan 23;235(4787):442-7 [2432664.001]
  • [Cites] Cancer. 1992 Dec 15;70(12):2747-53 [1451050.001]
  • [Cites] Annu Rev Cell Biol. 1993;9:541-73 [8280471.001]
  • [Cites] J Invest Dermatol. 1995 Aug;105(2):170-6 [7543547.001]
  • [Cites] J Cell Physiol. 1995 Dec;165(3):475-83 [7593226.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):190-6 [8548762.001]
  • [Cites] Int J Cancer. 1996 Feb 20;69(1):9-16 [8600068.001]
  • [Cites] Br J Cancer. 1996 Apr;73(8):972-8 [8611434.001]
  • [Cites] Br J Cancer. 1996 Aug;74(3):413-7 [8695357.001]
  • [Cites] Pathol Int. 1997 Jul;47(7):461-9 [9234385.001]
  • [Cites] Ann Thorac Surg. 1997 Oct;64(4):1204-11 [9354565.001]
  • [Cites] Cancer. 1998 Feb 15;82(4):642-50 [9477095.001]
  • [Cites] Cancer Res. 1998 Mar 1;58(5):1048-51 [9500469.001]
  • [Cites] Cancer. 1998 Sep 15;83(6):1153-62 [9740080.001]
  • [Cites] Curr Opin Cell Biol. 1998 Oct;10(5):602-8 [9818170.001]
  • [Cites] Ann Med. 1999 Feb;31(1):34-45 [10219712.001]
  • [Cites] Gynecol Oncol. 1999 Jun;73(3):372-82 [10366463.001]
  • [Cites] Gynecol Oncol. 1999 Oct;75(1):91-8 [10502432.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Mar;8(3):221-33 [17318226.001]
  • [Cites] Semin Cell Dev Biol. 2008 Feb;19(1):52-60 [17625931.001]
  • [Cites] Cancer Metastasis Rev. 2008 Dec;27(4):679-90 [18465089.001]
  • [Cites] Matrix Biol. 2009 Jan;28(1):3-10 [19010413.001]
  • [Cites] Integr Biol (Camb). 2009 Jun;1(5-6):382-93 [20023745.001]
  • [Cites] Biochim Biophys Acta. 2010 Jan;1803(1):3-19 [19631700.001]
  • [Cites] Cell. 2010 Apr 2;141(1):52-67 [20371345.001]
  • [Cites] Breast Cancer Res Treat. 1999 Dec;58(3):287-93 [10718490.001]
  • (PMID = 21151391.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; EC 3.4.24.24 / Matrix Metalloproteinase 2
  • [Other-IDs] NLM/ PMC2993228
  • [Keywords] NOTNLM ; CNS metastasis / Matrix metalloproteinases (MMP) / angiogenesis / lung cancer
  •  go-up   go-down


73. Naor R, Domankevich V, Shemer S, Sominsky L, Rosenne E, Levi B, Ben-Eliyahu S: Metastatic-promoting effects of LPS: sexual dimorphism and mediation by catecholamines and prostaglandins. Brain Behav Immun; 2009 Jul;23(5):611-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic-promoting effects of LPS: sexual dimorphism and mediation by catecholamines and prostaglandins.
  • Here we studied the effects of the proinflammatory agent, LPS, on MADB106 lung tumor retention (LTR), and sought to elucidate underlying mechanisms and sexual dimorphism.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NADOLOL .
  • Hazardous Substances Data Bank. INDOMETHACIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocrinology. 2004 Nov;145(11):5021-32 [15256495.001]
  • [Cites] Br J Cancer. 1980 Jul;42(1):52-7 [7426329.001]
  • [Cites] J Immunol. 1983 Aug;131(2):1024-7 [6863925.001]
  • [Cites] Int J Dermatol. 1984 Sep;23(7):444-52 [6386712.001]
  • [Cites] J Immunol. 1985 Apr;134(4):2783-9 [3871818.001]
  • [Cites] J Exp Med. 1989 Apr 1;169(4):1373-89 [2466943.001]
  • [Cites] J Exp Med. 1990 Jan 1;171(1):197-210 [2295876.001]
  • [Cites] J Immunol. 1992 Jun 1;148(11):3658-65 [1588052.001]
  • [Cites] J Biol Chem. 1992 Dec 25;267(36):25934-8 [1464605.001]
  • [Cites] J Exp Med. 1994 Dec 1;180(6):2365-70 [7525853.001]
  • [Cites] Jpn J Pharmacol. 1994 Jun;65(2):113-20 [7967224.001]
  • [Cites] Arch Surg. 1994 Nov;129(11):1172-8 [7979949.001]
  • [Cites] Brain Behav Immun. 1994 Sep;8(3):241-50 [7865895.001]
  • [Cites] Ann Rheum Dis. 1995 Jan;54(1):6-16 [7880125.001]
  • [Cites] Stroke. 1995 Mar;26(3):361-7 [7886707.001]
  • [Cites] Jpn J Physiol. 1994;44(6):693-703 [7760523.001]
  • [Cites] Brain Behav Immun. 1995 Jun;9(2):149-62 [7549037.001]
  • [Cites] Br J Pharmacol. 1995 Jun;115(4):672-6 [7582489.001]
  • [Cites] Nat Med. 1996 Apr;2(4):457-60 [8597957.001]
  • [Cites] J Natl Cancer Inst. 1996 Feb 21;88(3-4):198-205 [8632494.001]
  • [Cites] Brain Behav Immun. 1996 Jun;10(2):77-91 [8811932.001]
  • [Cites] Br J Cancer. 1996 Dec;74(12):1900-7 [8980388.001]
  • [Cites] Int J Parasitol. 1996 Nov;26(11):1311-5 [9024877.001]
  • [Cites] Hepatogastroenterology. 1997 Mar-Apr;44(14):477-83 [9164522.001]
  • [Cites] Br J Dermatol. 1997 May;136(5):657-65 [9205495.001]
  • [Cites] Am J Reprod Immunol. 1997 Jul;38(1):46-54 [9266010.001]
  • [Cites] Am J Physiol. 1997 Dec;273(6 Pt 2):R1885-90 [9435641.001]
  • [Cites] J Immunol. 1998 Apr 1;160(7):3251-8 [9531281.001]
  • [Cites] FASEB J. 1998 Sep;12(12):1063-73 [9737710.001]
  • [Cites] Biochem Pharmacol. 1998 Nov 1;56(9):1079-87 [9802316.001]
  • [Cites] Arch Surg. 1998 Nov;133(11):1200-5 [9820351.001]
  • [Cites] Br J Pharmacol. 1998 Nov;125(6):1297-303 [9863660.001]
  • [Cites] N Engl J Med. 1999 Jan 14;340(2):115-26 [9887164.001]
  • [Cites] Curr Opin Immunol. 1999 Feb;11(1):19-22 [10047547.001]
  • [Cites] Int J Cancer. 1999 Mar 15;80(6):880-8 [10074922.001]
  • [Cites] J Clin Immunol. 1999 Jul;19(4):203-14 [10471974.001]
  • [Cites] Am J Physiol. 1999 Sep;277(3 Pt 2):H924-30 [10484412.001]
  • [Cites] Br J Pharmacol. 2004 Dec;143(8):1033-41 [15477226.001]
  • [Cites] Brain Behav Immun. 2005 Mar;19(2):114-26 [15664784.001]
  • [Cites] Anticancer Res. 2005 Mar-Apr;25(2A):1101-8 [15868952.001]
  • [Cites] Cancer. 2005 Jul 15;104(2):223-8 [15937911.001]
  • [Cites] Br J Pharmacol. 2005 Aug;145(7):872-9 [15912135.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2005 Nov;289(5):H1843-50 [16006544.001]
  • [Cites] Clin Infect Dis. 2005 Nov 15;41 Suppl 7:S490-7 [16237652.001]
  • [Cites] Shock. 2005 Dec;24 Suppl 1:94-100 [16374380.001]
  • [Cites] Trends Immunol. 2006 Jan;27(1):24-31 [16316783.001]
  • [Cites] Circulation. 2006 Feb 14;113(6):e85-151 [16407573.001]
  • [Cites] Ann Surg. 2006 May;243(5):693-8; discussion 698-700 [16633005.001]
  • [Cites] Neurologist. 2006 May;12(3):140-8 [16688015.001]
  • [Cites] J Reprod Immunol. 2006 Aug;71(1):12-27 [16574244.001]
  • [Cites] Immunol Res. 2006;34(3):177-92 [16891670.001]
  • [Cites] Physiol Behav. 2006 Sep 30;89(2):146-55 [16842830.001]
  • [Cites] Allergy. 2006 Nov;61(11):1336-43 [17002711.001]
  • [Cites] Cancer Metastasis Rev. 2006 Sep;25(3):387-408 [17043764.001]
  • [Cites] Ann N Y Acad Sci. 2006 Nov;1088:100-15 [17192559.001]
  • [Cites] J Neuroimmunol. 2007 Mar;184(1-2):53-68 [17188755.001]
  • [Cites] Prog Brain Res. 2007;162:3-14 [17645911.001]
  • [Cites] Autoimmun Rev. 2007 Nov;7(1):1-7 [17967717.001]
  • [Cites] J Dtsch Dermatol Ges. 2007 Nov;5(11):1015-28 [17976144.001]
  • [Cites] Ann Clin Psychiatry. 2007 Oct-Dec;19(4):247-55 [18058282.001]
  • [Cites] Nat Rev Neurosci. 2008 Jan;9(1):46-56 [18073775.001]
  • [Cites] J Neuroimmunol. 2008 Jan;193(1-2):113-9 [18037507.001]
  • [Cites] Ann Surg Oncol. 2008 Jul;15(7):2042-52 [18398660.001]
  • [Cites] Allergy. 2008 Jan;63(1):47-57 [17822448.001]
  • [Cites] Br J Cancer. 1999 Dec;81(8):1311-7 [10604727.001]
  • [Cites] J Mol Med (Berl). 1999 Nov;77(11):769-80 [10619437.001]
  • [Cites] Intensive Care Med. 2000 Feb;26(2):167-72 [10784304.001]
  • [Cites] Anaesthesia. 2000 May;55(5):442-9 [10792135.001]
  • [Cites] Neurosci Biobehav Rev. 2000 Aug;24(6):627-38 [10940438.001]
  • [Cites] Shock. 2000 Aug;14(2):81-90 [10947147.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):782-7 [10963608.001]
  • [Cites] Pharmacol Rev. 2000 Dec;52(4):595-638 [11121511.001]
  • [Cites] Neuroimmunomodulation. 2000;8(3):154-64 [11124582.001]
  • [Cites] J Clin Invest. 2001 Jan;107(1):3-6 [11134170.001]
  • [Cites] Lancet. 2001 Feb 17;357(9255):539-45 [11229684.001]
  • [Cites] Int Immunopharmacol. 2001 Jun;1(6):983-93 [11407317.001]
  • [Cites] Anesthesiology. 2001 Jun;94(6):1066-73 [11465599.001]
  • [Cites] Nat Immunol. 2001 Sep;2(9):777-80 [11526384.001]
  • [Cites] Circ Res. 2001 Oct 26;89(9):823-30 [11679413.001]
  • [Cites] Allergy. 2001 Dec;56(12):1192-6 [11736749.001]
  • [Cites] J Endotoxin Res. 2001;7(5):385-8 [11753208.001]
  • [Cites] J Pharmacol Exp Ther. 2002 Feb;300(2):367-75 [11805193.001]
  • [Cites] Endocr Rev. 2002 Feb;23(1):90-119 [11844745.001]
  • [Cites] Ann N Y Acad Sci. 2001 Mar;933:222-34 [12000023.001]
  • [Cites] Nat Rev Cancer. 2002 Apr;2(4):301-10 [12001991.001]
  • [Cites] Int J Cancer. 2002 Oct 10;101(5):415-22 [12216068.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2002 Jul;24(4):367-9 [12408766.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2003 Feb;284(2):R422-32 [12399247.001]
  • [Cites] Annu Rev Immunol. 2003;21:335-76 [12524386.001]
  • [Cites] Brain Behav Immun. 2003 Feb;17 Suppl 1:S5-10 [12615180.001]
  • [Cites] Ann Surg Oncol. 2003 May;10(4):469-79 [12734098.001]
  • [Cites] Acta Psychiatr Scand. 2003 Sep;108(3):163-74 [12890270.001]
  • [Cites] Curr Opin Pharmacol. 2003 Aug;3(4):352-61 [12901943.001]
  • [Cites] Stroke. 2003 Oct;34(10):2518-32 [14500942.001]
  • [Cites] Ann Surg Oncol. 2003 Oct;10(8):972-92 [14527919.001]
  • [Cites] J Endocrinol Invest. 2003 Oct;26(10):1013-22 [14759076.001]
  • [Cites] Endocrinology. 2004 Apr;145(4):1889-97 [14684616.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2004 May;286(5):H2010-9 [14684367.001]
  • [Cites] Front Biosci. 2004 Sep 1;9:3156-62 [15353345.001]
  • [Cites] Cancer Cell. 2004 Sep;6(3):297-305 [15380520.001]
  • [Cites] Immunology. 2004 Oct;113(2):153-62 [15379975.001]
  • [Cites] Nature. 2004 Sep 23;431(7007):405-6 [15385993.001]
  • (PMID = 18951972.001).
  • [ISSN] 1090-2139
  • [Journal-full-title] Brain, behavior, and immunity
  • [ISO-abbreviation] Brain Behav. Immun.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA125456-02; United States / NCI NIH HHS / CA / R01 CA125456; United States / NCI NIH HHS / CA / R01 CA125456-02
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adrenergic beta-Antagonists; 0 / Catecholamines; 0 / Cyclooxygenase Inhibitors; 0 / Interleukin-6; 0 / Lipopolysaccharides; 0 / Prostaglandins; 0 / Tumor Necrosis Factor-alpha; 42200-33-9 / Nadolol; W980KJ009P / Corticosterone; XXE1CET956 / Indomethacin
  • [Other-IDs] NLM/ NIHMS126661; NLM/ PMC2723727
  •  go-up   go-down


74. Okuma Y, Hosomi Y, Takagi Y, Miyamoto S, Shimokawa T, Iguchi M, Okamura T, Saito K, Shibuya M: Long-term survival following metachronous intratumoral hemorrhage in an HIV-infected patient with lung cancer. Int J Clin Oncol; 2010 Oct;15(5):515-8
HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival following metachronous intratumoral hemorrhage in an HIV-infected patient with lung cancer.
  • Due to the spread of highly active antiretroviral therapy (HAART), HIV-infected patients now survive longer, and metastatic non-AIDS-defining carcinoma is increasing.
  • He was diagnosed as having lung adenocarcinoma and was found to have a brain metastasis with bleeding.
  • The patient underwent a second craniotomy and removal of hematoma, followed by whole-brain radiotherapy.
  • This lung cancer patient had been alive for 17 months despite the coexistence of two disorders with a poor prognosis, HIV infection and bleeding brain metastases from lung cancer.
  • This case revealed that physicians must include non-AIDS-defining cancer metastasis to the brain in the differential diagnosis of HIV-infected patients when they show stroke-like symptoms, and such patients may respond to treatment as well as non-HIV-infected patients with advanced lung cancer.
  • [MeSH-major] Adenocarcinoma / secondary. Brain Neoplasms / secondary. HIV Infections / complications. Intracranial Hemorrhages / etiology. Lung Neoplasms / pathology


75. Jahnke A, Domke R, Makovitzky J, Nizze H, Briese V: Vaginal metastasis of lung cancer: a case report. Anticancer Res; 2005 May-Jun;25(3A):1645-8
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vaginal metastasis of lung cancer: a case report.
  • BACKGROUND: Lung cancer is the second most common malignant tumor, with increasing incidence in the female population.
  • The most frequent metastatic sites are the regional lymph nodes and surrounding areas as well as liver, adrenal gland, bones and brain.
  • Metastases in the vagina of primary lung cancer have not been previously reported.
  • CASE REPORT: Lung cancer was diagnosed in a 67-year-old, postmenopausal woman.
  • Two years following partial lung resection (right apical lobe, R0-resection, CR), the patient complained of increasing problems with urination.
  • Histological and immunohistochemical examinations of a vaginal excisional biopsy revealed metastatic adenocarcinoma, with the staining reactivity as primary lung neoplasm.
  • This is the first report of vaginal metastases from primary lung cancer.
  • We suggest that adenocarcinoma especially tend to form metastases in the female genital tract.
  • [MeSH-major] Lung Neoplasms / pathology. Vaginal Neoplasms / secondary

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Vaginal cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16033075.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


76. Sundermeyer ML, Meropol NJ, Rogatko A, Wang H, Cohen SJ: Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin Colorectal Cancer; 2005 Jul;5(2):108-13
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changing patterns of bone and brain metastases in patients with colorectal cancer.
  • BACKGROUND: Therapeutic advances for patients with metastatic colorectal cancer (CRC) have been associated with prolonged survival.
  • This study was undertaken to test the hypothesis that expanded treatment options and resultant improved survival for patients with metastatic CRC are associated with an increased incidence of metastases at uncommon sites.
  • PATIENTS AND METHODS: Patients with metastatic CRC evaluated from 1993 to 2002 at the Fox Chase Cancer Center were identified.
  • Medical records were abstracted to obtain the following: date of diagnosis/metastasis, primary tumor site, therapeutic agents received, survival, and site(s) of metastases.
  • Incidence of bone and brain metastases were 10.4% (95% CI, 8.6%-12.4%) and 3% (95% CI, 2.2%-4.5%), respectively.
  • Patients with lung metastases were more likely to have bone metastases (16.1% vs. 6.4%; P < 0.0001) or brain metastases (6.2% vs. 1.2%; P < 0.0001) than those without.
  • CONCLUSION: These data demonstrate that the incidence of bone and brain metastases in patients with CRC is more common than previously reported and is associated with receipt of multiple systemic treatments.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma / secondary. Bone Neoplasms / epidemiology. Bone Neoplasms / secondary. Brain Neoplasms / epidemiology. Brain Neoplasms / secondary. Colorectal Neoplasms / pathology


77. Yang L, Liu XY, Fang J, An TT, Wu MN: [Gefitinib in the treatment of advanced non-small cell lung cancer]. Zhonghua Zhong Liu Za Zhi; 2006 Jun;28(6):474-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gefitinib in the treatment of advanced non-small cell lung cancer].
  • OBJECTIVE: To investigate the efficacy, time to progression, survival time and toxicity of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor Gefitinib (Iressa), a target therapy agent, in the treatment of advanced non-small cell lung cancer (NSCLC), and to analyze the factors affecting the efficacy and patients' survival.
  • The disease control rate of those who had adenocarcinoma, or received second-line chemotherapy or developed skin toxicity was significantly better than the other patients (P value = 0.04, 0.02, 0.00, respectively). (2) Median time to progress (TIP) was 5.0 months (95% CI 3.26-6.74). (3) Median following-up duration was 7.5 months (1-18.
  • Non-smoker, stable diseases, skin toxicities, and controlled metastatic diseases during the treatment of gefitinib were the favorable factors affecting the survival (P value = 0.00, 0.00, 0.00, 0.01, respectively). (4) The main toxicity of gefitinib was grade I or II skin toxicity.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Disease Progression. Exanthema / chemically induced. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17152500.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


78. Stinchcombe TE, Socinski MA: Current treatments for advanced stage non-small cell lung cancer. Proc Am Thorac Soc; 2009 Apr 15;6(2):233-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current treatments for advanced stage non-small cell lung cancer.
  • Lung cancer remains the leading cause of cancer mortality in the United States, and the majority of patients will have non-small cell lung cancer (NSCLC) and will present with locally advanced or metastatic disease.
  • In the United States, the most common histology is adenocarcinoma, followed by squamous cell, large cell, and not otherwise specified.
  • To receive bevacizumab, patients are required to have nonsquamous histology, a PS of 0 or 1, and no evidence of brain metastases, hemoptysis, uncontrolled hypertension, and no need for therapeutic anticoagulation.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy


79. Tartarone A: Pemetrexed in heavily pretreated non-small-cell lung cancer patients: case report and review of the literature. Future Oncol; 2010 Dec;6(12):1937-40
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pemetrexed in heavily pretreated non-small-cell lung cancer patients: case report and review of the literature.
  • To date, there is no standard treatment for patients with metastatic non-small-cell lung cancer after multiple previous lines of chemotherapy.
  • Pemetrexed in combination with cisplatin or as a single agent demonstrated significant activity in patients with nonsquamous non-small-cell lung cancer with a good toxicity profile.
  • In this article, we present a case of pulmonary adenocarcinoma treated with pemetrexed after five lines of treatment, including the cytotoxic agents cisplatin plus vinorelbine, docetaxel, gemcitabine and the tyrosine kinase inhibitor erlotinib.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Glutamates / therapeutic use. Guanine / analogs & derivatives
  • [MeSH-minor] Bone Neoplasms / drug therapy. Bone Neoplasms / radiotherapy. Bone Neoplasms / secondary. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Brain Neoplasms / secondary. Combined Modality Therapy. Fatal Outcome. Humans. Male. Middle Aged. Neoplasm Staging. Palliative Care. Pemetrexed

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. PEMETREXED .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21142866.001).
  • [ISSN] 1744-8301
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine
  •  go-up   go-down


80. Takei H, Powell SZ: Tumor-to-tumor metastasis to the central nervous system. Neuropathology; 2009 Jun;29(3):303-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningioma is the most common intracranial host tumor, with the breast and lung being the most common primary sites.
  • We report herein two such cases of metastasis from pulmonary adenocarcinoma and malignant melanoma (MM) of vulva, respectively.
  • Case 1: a 69-year-old female smoker who had a history of right upper lobectomy of lung for adenocarcinoma presented with a headache and altered mental status, and was found to have a left temporal contrast-enhancing mass with massive surrounding edema on MRI.
  • The resection specimen revealed foci of metastatic adenocarcinoma within a microcystic meningioma.
  • Histologic examination showed a fibroblastic meningioma with a focus of metastatic MM.
  • Case 1 is the first case report describing a microcystic variant of meningioma harboring metastatic carcinoma.
  • Although MM is one of the most common metastatic brain tumors, MM-to-meningioma metastasis is reportedly extremely rare, but can occur.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / secondary. Meningioma / pathology. Meningioma / secondary
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Aged. Brain / pathology. Brain / surgery. Fatal Outcome. Female. Humans. Immunohistochemistry. Lung Neoplasms / pathology. Lung Neoplasms / surgery. Magnetic Resonance Imaging. Melanoma / pathology. Melanoma / surgery. Treatment Outcome. Vulvar Neoplasms / pathology. Vulvar Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18647266.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


81. Zhong XJ, Li DT, Li XL, Mu DB, Zhang XG, Luo JY: [Comparison of the characteristics in recurrence and metastasis between bronchioloalveolar carcinoma and other lung adenocarcinomas]. Ai Zheng; 2007 Jul;26(7):785-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison of the characteristics in recurrence and metastasis between bronchioloalveolar carcinoma and other lung adenocarcinomas].
  • Although bronchioloalveolar carcinoma is a subtype of lung adenocarcinoma, its biological features are better than those of other lung adenocarcinomas.
  • This study was to analyze differences in metastatic activity between bronchioloalveolar carcinoma and other lung adenocarcinomas.
  • METHODS: The expression of E-Cadherin, Collagen IV, vascular endothelial growth factor receptor-2 (VEGFR-2), matrix metalloproteinase-9 (MMP-9), and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in 28 specimens of stage I bronchioloalveolar carcinoma confirmed pathologically and 40 specimens of other stage I lung adenocarcinomas were detected by immunohistochemistry.
  • RESULTS: The 5-year survival rate was significantly higher in ths patients with bronchioloalveolar carcinoma than in the patients with other lung adenocarcinomas (88.7% vs. 57.3%, P < 0.05).
  • The intrathoracic recurrence rate was significantly higher and the extrathoracic metastasis rate was significantly lower in the patients with bronchioloalveolar carcinoma than in the patients with other lung adenocarcinomas (75% vs. 33.3%, 25% vs. 66.7%, P < 0.05).
  • The positive rates of Collagen IV, E-Cadherin and TIMP-1 were significantly higher in bronchioloalveolar carcinoma than in other lung adenocarcinomas (78.6% vs. 42.5%, 78.6% vs. 40.0%, 67.5% vs. 42.9%, all P < 0.01).
  • The positive rate of VEGFR-2 was significantly higher in other lung adenocarcinomas than in bronchioloalveolar carcinoma (85.7% vs. 77.5%, P < 0.05).
  • There was no significant difference in the positive rate of MMP-9 between bronchioloalveolar carcinoma and other lung adenocarcinomas (85.0% vs. 78.6%, P = 0.494).
  • CONCLUSION: As compared with other lung adenocarcinomas, stage I bronchioloalveolar carcinoma is less aggressive in clinical behavior and likely to develop intrathoracic recurrence, with less extrathoracic metastases and better prognosis.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Collagen Type IV / metabolism. Lung Neoplasms / pathology. Neoplasm Recurrence, Local
  • [MeSH-minor] Bone Neoplasms / secondary. Brain Neoplasms / secondary. Cadherins / metabolism. Female. Follow-Up Studies. Humans. Male. Matrix Metalloproteinase 9 / metabolism. Middle Aged. Neoplasm Staging. Survival Rate. Tissue Inhibitor of Metalloproteinase-1 / metabolism. Vascular Endothelial Growth Factor Receptor-2 / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17626761.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cadherins; 0 / Collagen Type IV; 0 / Tissue Inhibitor of Metalloproteinase-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


82. Yano T, Haro A, Yoshida T, Morodomi Y, Ito K, Shikada Y, Shoji F, Maruyama R, Maehara Y: Prognostic impact of local treatment against postoperative oligometastases in non-small cell lung cancer. J Surg Oncol; 2010 Dec 1;102(7):852-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic impact of local treatment against postoperative oligometastases in non-small cell lung cancer.
  • OBJECTIVES: In this study, we investigated prognostic factors associated with survival after distantly metastatic recurrence in surgically resected non-small cell lung cancer (NSCLC), and clarified the influence of local treatment on the prognosis for oligometastatic recurrence.
  • The targeted metastatic organs were brain in 14 patients, bone in 14, lungs in 12, and other organs in 4.
  • Significant prognostic factors for postrecurrence survival included adenocarcinoma histology, long disease-free interval (DFI) (1 year or longer), and the performance of local treatment for oligometastases.
  • [MeSH-major] Bone Neoplasms / surgery. Brain Neoplasms / surgery. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Neoplasm Recurrence, Local / surgery


83. Masutani K, Fujisaki K, Maeda H, Toyonaga J, Inoshima I, Takayama K, Katafuchi R, Hirakata H, Tsuruya K, Iida M: Tubulointerstitial nephritis and IgA nephropathy in a patient with advanced lung cancer treated with long-term gefitinib. Clin Exp Nephrol; 2008 Oct;12(5):398-402
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tubulointerstitial nephritis and IgA nephropathy in a patient with advanced lung cancer treated with long-term gefitinib.
  • Two years prior to admission, she was diagnosed with lung adenocarcinoma and multiple bone and brain metastases, and was treated with gefitinib (250 mg/day).
  • Treatment for 6 months induced partial response with 30% regression of the primary lung tumor, and resolution of metastatic tumors.
  • In consideration of the prognosis of lung cancer and complication of immunosuppressive treatment, we continued gefitinib only and closely followed-up the clinical course in the outpatient clinic.
  • However, the lung cancer started to increase in size.
  • [MeSH-major] Adenocarcinoma / drug therapy. Glomerulonephritis, IGA / chemically induced. Lung Neoplasms / drug therapy. Nephritis, Interstitial / chemically induced. Quinazolines / adverse effects. Quinazolines / therapeutic use

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2549-56 [16735708.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2240-50 [11980995.001]
  • [Cites] Arch Pathol Lab Med. 2005 Aug;129(8):1044-6 [16048398.001]
  • [Cites] Clin Exp Nephrol. 2005 Sep;9(3):262-3 [16189639.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):5054-9 [12941834.001]
  • [Cites] Lancet. 2003 Jan 11;361(9352):137-9 [12531582.001]
  • [Cites] Kidney Int. 2004 Nov;66(5):1805-14 [15496151.001]
  • [Cites] Am J Physiol. 1988 Dec;255(6 Pt 2):F1191-6 [3264462.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2504-5 [15197213.001]
  • [Cites] Clin Exp Nephrol. 2004 Dec;8(4):297-303 [15619027.001]
  • [Cites] FASEB J. 2004 May;18(7):926-8 [15033924.001]
  • [Cites] Nihon Kokyuki Gakkai Zasshi. 2003 Aug;41(8):565-8 [14503345.001]
  • [Cites] Kidney Int. 2003 Nov;64(5):1573-9 [14531789.001]
  • [Cites] J Biol Chem. 1999 Jun 18;274(25):17612-8 [10364198.001]
  • (PMID = 18575950.001).
  • [ISSN] 1342-1751
  • [Journal-full-title] Clinical and experimental nephrology
  • [ISO-abbreviation] Clin. Exp. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


84. Bugalho P, Chorão M, Fontoura P: Miliary brain metastases from primary gastric small cell carcinoma: illustrating the seed and soil hypothesis. J Neurooncol; 2005 May;73(1):53-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Miliary brain metastases from primary gastric small cell carcinoma: illustrating the seed and soil hypothesis.
  • Miliary metastases are a very rare condition usually found in the context of primary lung tumor (small cell and adenocarcinoma), and refer to the existence of numerous tumor nodules in widespread areas of the brain.
  • Besides pulmonary neoplasia, pancreatic adenocarcinoma and malignant melanoma have also been implicated in some cases of miliary metastases.
  • The pathological resemblance of PSCGC with small cell lung carcinoma may correspond to an underlying similarity in biological behavior, which accounts for this particular pattern of metastatic spreading, as proposed in the seed and soil hypothesis.
  • [MeSH-major] Brain Neoplasms / secondary. Carcinoma, Neuroendocrine / pathology. Carcinoma, Small Cell / secondary. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. STREPTOZOTOCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15933819.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 5W494URQ81 / Streptozocin; U3P01618RT / Fluorouracil
  •  go-up   go-down


85. William WN Jr, Zinner RG, Karp DD, Oh YW, Glisson BS, Phan SC, Stewart DJ: Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung cancer. J Thorac Oncol; 2007 Aug;2(8):745-50
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung cancer.
  • In patients with lung cancer, motexafin gadolinium has been shown to increase the time to neurologic progression when given in combination with whole-brain radiotherapy in randomized phase III studies.
  • METHODS: In this one-arm, open label, phase I, dose-escalation study, we administered docetaxel (75 mg/m2), cisplatin (75 mg/m2), and motexafin gadolinium every 3 weeks to patients with metastatic non-small cell lung cancer.
  • CONCLUSIONS: The regimen studied was tolerable and showed activity in patients with metastatic non-small cell lung cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Adenocarcinoma / secondary. Adult. Aged. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / secondary. Cisplatin / administration & dosage. Dose-Response Relationship, Drug. Female. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Lung Neoplasms / radiotherapy. Male. Maximum Tolerated Dose. Metalloporphyrins / administration & dosage. Middle Aged. Prognosis. Survival Rate. Taxoids / administration & dosage

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17762342.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5-P30 CA16672-32
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Metalloporphyrins; 0 / Taxoids; 15H5577CQD / docetaxel; 6433A42F4F / motexafin gadolinium; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


86. Saif MW, Galanina N, Ravage-Mass L, Kaley K, Cornfeld D, Lamb L, Chhieng D: Bone Metastasis as the Only Metastatic Site in a Patient with Pancreatic Cancer following Distal Pancreatectomy. Case Rep Med; 2010;2010

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone Metastasis as the Only Metastatic Site in a Patient with Pancreatic Cancer following Distal Pancreatectomy.
  • Other less common sites are the lung, brain, kidney, and bone.
  • Here, we report an interesting case of pancreatic adenocarcinoma with exclusive bone metastases and discuss briefly the possible pathogenesis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20862374.001).
  • [ISSN] 1687-9635
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2938458
  •  go-up   go-down


87. Sloan EK, Priceman SJ, Cox BF, Yu S, Pimentel MA, Tangkanangnukul V, Arevalo JM, Morizono K, Karanikolas BD, Wu L, Sood AK, Cole SW: The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res; 2010 Sep 15;70(18):7042-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The sympathetic nervous system induces a metastatic switch in primary breast cancer.
  • Stress-induced neuroendocrine activation had a negligible effect on growth of the primary tumor but induced a 30-fold increase in metastasis to distant tissues including the lymph nodes and lung.
  • [MeSH-major] Adenocarcinoma / pathology. Mammary Neoplasms, Experimental / pathology. Stress, Physiological / physiology. Sympathetic Nervous System / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [Cites] J Neuroimmunol. 1993 Nov-Dec;48(2):151-60 [8227313.001]
  • [Cites] Brain Behav Immun. 1994 Mar;8(1):14-23 [8003768.001]
  • [Cites] Int J Cancer. 1994 Aug 15;58(4):512-6 [8056447.001]
  • [Cites] J Neuroimmunol. 1994 Sep;53(2):173-80 [8071431.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1995;35:417-48 [7598501.001]
  • [Cites] Brain Res Bull. 1998;45(2):183-7 [9443838.001]
  • [Cites] J Immunol. 1998 Apr 1;160(7):3251-8 [9531281.001]
  • [Cites] J Immunol. 1998 Jul 15;161(2):610-6 [9670934.001]
  • [Cites] J Invest Dermatol. 1999 May;112(5):802-9 [10233775.001]
  • [Cites] Am J Physiol. 1999 May;276(5 Pt 2):R1461-8 [10233040.001]
  • [Cites] J Neuroimmunol. 1999 May 3;96(2):182-9 [10337916.001]
  • [Cites] Brain Behav Immun. 2005 Mar;19(2):114-26 [15664784.001]
  • [Cites] Nat Med. 2005 Mar;11(3):346-52 [15711560.001]
  • [Cites] J Interferon Cytokine Res. 2005 Jul;25(7):384-94 [16022583.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9426-35 [16230406.001]
  • [Cites] Nat Rev Cancer. 2006 Mar;6(3):240-8 [16498446.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1105-11 [16505430.001]
  • [Cites] J Virol. 2006 May;80(9):4326-35 [16611891.001]
  • [Cites] Breast Cancer Res. 2006;8(2):R20 [16608535.001]
  • [Cites] Nat Med. 2006 Aug;12(8):939-44 [16862152.001]
  • [Cites] J Neurosci. 2007 Aug 15;27(33):8857-65 [17699667.001]
  • [Cites] J Biol Chem. 2007 Oct 12;282(41):29919-26 [17716980.001]
  • [Cites] Curr Neurovasc Res. 2008 Feb;5(1):1-12 [18289016.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Aug;5(8):466-75 [18493231.001]
  • [Cites] Clin Cancer Res. 2008 Nov 1;14(21):6839-46 [18980978.001]
  • [Cites] J Clin Oncol. 2009 Jul 20;27(21):3418-9 [19470918.001]
  • [Cites] Cancer Cell. 2009 Aug 4;16(2):81-2 [19647215.001]
  • [Cites] Cancer Cell. 2009 Aug 4;16(2):91-102 [19647220.001]
  • [Cites] Blood. 2010 Feb 18;115(7):1461-71 [20008303.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Mar 23;107(12):5681-6 [20176930.001]
  • [Cites] Arch Intern Med. 2000 Feb 14;160(3):349-53 [10668837.001]
  • [Cites] Am J Public Health. 2000 Oct;90(10):1601-7 [11029995.001]
  • [Cites] Pharmacol Rev. 2001 Mar;53(1):1-24 [11171937.001]
  • [Cites] Int J Oncol. 2002 Jul;21(1):153-7 [12063562.001]
  • [Cites] BMJ. 2002 Jun 15;324(7351):1420 [12065263.001]
  • [Cites] Cancer. 2002 Nov 15;95(10):2237-42 [12412179.001]
  • [Cites] Am J Epidemiol. 2003 Mar 1;157(5):415-23 [12615606.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1299-308 [12973855.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1504-13 [14508839.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4514-21 [14555525.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):71-8 [14708027.001]
  • [Cites] World J Surg. 2004 Mar;28(3):327-30 [14961184.001]
  • [Cites] Rev Epidemiol Sante Publique. 2004 Feb;52(1):53-65 [15107693.001]
  • [Cites] Cancer Causes Control. 2004 Aug;15(6):535-41 [15280632.001]
  • [Cites] Int J Cancer. 2004 Nov 1;112(2):231-8 [15352035.001]
  • [Cites] Annu Rev Neurosci. 1992;15:87-114 [1575451.001]
  • [Cites] BMJ. 1992 Apr 25;304(6834):1078-81 [1586819.001]
  • [Cites] J Psychosom Res. 1992 Sep;36(6):531-41 [1640391.001]
  • (PMID = 20823155.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA138687; United States / NCI NIH HHS / CA / CA116778; United States / NCI NIH HHS / CA / CA109298; United States / NCI NIH HHS / CA / R01 CA116778; United States / NCI NIH HHS / CA / R01 CA160890; United States / NCI NIH HHS / CA / R01 CA109298; United States / NCI NIH HHS / CA / R01 CA110793; United States / NCI NIH HHS / CA / CA110793; United States / NCI NIH HHS / CA / R21 CA138687; United States / NCI NIH HHS / CA / R21 CA138687-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS227759; NLM/ PMC2940980
  •  go-up   go-down


88. Rossi D, Dennetta D, Ugolini M, Alessandroni P, Catalano V, Fedeli SL, Giordani P, Casadei V, Baldelli AM, Graziano F, Catalano G: Weekly paclitaxel in elderly patients (aged &gt; or = 70 years) with advanced non-small-cell lung cancer: an alternative choice? Results of a phase II study. Clin Lung Cancer; 2008 Sep;9(5):280-4
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weekly paclitaxel in elderly patients (aged > or = 70 years) with advanced non-small-cell lung cancer: an alternative choice? Results of a phase II study.
  • PURPOSE: Paclitaxel and platinum-based chemotherapy is considered to be a standard approach for locally advanced and metastatic non-small-cell lung cancer (NSCLC).
  • The aim of our study was to investigate the activity and safety of weekly paclitaxel in elderly patients with locally advanced (stage IIIB) and metastatic (stage IV) NSCLC.
  • CONCLUSION: Our study confirmed that paclitaxel 80 mg/m2 weekly is active in patients with locally advanced and metastatic NSCLC with a good safety profile; this schedule might be considered an alternative choice to gemcitabine or vinorelbine as first-line treatment in elderly patients, particularly patients with comorbidities.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Paclitaxel / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Aged. Aged, 80 and over. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Carcinoma / drug therapy. Carcinoma / secondary. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Female. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Male. Prognosis. Salvage Therapy. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18824450.001).
  • [ISSN] 1525-7304
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


89. Kaira K, Endo M, Asakura K, Tsuya A, Nakamura Y, Naito T, Murakami H, Takahashi T, Yamamoto N: Ratio of standardized uptake value on PET helps predict response and outcome after chemotherapy in advanced non-small cell lung cancer. Ann Nucl Med; 2010 Dec;24(10):697-705
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ratio of standardized uptake value on PET helps predict response and outcome after chemotherapy in advanced non-small cell lung cancer.
  • BACKGROUND: The maximum standardized uptake value (SUV(max)) on (18)F-fluorodeoxyglucose-positron emission tomography ((18)F-FDG PET) within the primary tumor may predict outcome in patients with surgically resected non-small cell lung cancer (NSCLC).
  • Thus, we evaluated the ratio of SUV(max) of the metastatic tumor to the primary tumor (M/P ratio) to determine whether it could be a useful marker in predicting response and outcome after chemotherapy in advanced NSCLC.
  • METHODS: Chemo-naïve patients with advanced NSCLC who had locoregional lymph nodes and/or distant metastases other than brain, were eligible for inclusion in this study.
  • However, the outcome of non-adenocarcinoma was unaffected by T/M ratio and SUV(max).
  • CONCLUSION: High M/P ratio was associated with a poor response to initial chemotherapy and was a significant independent factor in predicting poor outcome in advanced NSCLC patients with metastatic tumors other than in brain.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / radionuclide imaging. Lung Neoplasms / drug therapy. Lung Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20824397.001).
  • [ISSN] 1864-6433
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


90. Kosmas C, Tsavaris N, Syrigos K, Koutras A, Tsakonas G, Makatsoris T, Mylonakis N, Karabelis A, Stathopoulos GP, Kalofonos HP: A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens. Cancer Chemother Pharmacol; 2007 Jan;59(1):51-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.
  • PURPOSE: Treatment options in patients with recurrent non-small cell lung cancer (NSCLC) remain limited as a result of poor activity of most agents after failure of platinum-based therapy.
  • RESULTS: Forty-nine patients entered the phase I and II part of the study (phase I: 12-phase II: 37 + 3 at DL-3), and 40 patients were evaluable for a response in phase II and all for toxicity: median age, 61 years (range 36-74); PS, 1 (0-2); gender, 43 males/6 females-histologies; adenocarcinoma, 25; squamous, 20; large cell, 4.
  • Metastatic sites included lymph nodes, 38; bone, 5; liver, 4; brain, 3; lung nodules, 14; adrenals, 13; other, 3.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16622691.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Bridged Compounds; 0 / Organoplatinum Compounds; 0 / Taxoids; 0W860991D6 / Deoxycytidine; 1605-68-1 / taxane; 7673326042 / irinotecan; B76N6SBZ8R / gemcitabine; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


91. Kulig J, Matyja A, Kowalewski M, Kratochwil M: [Abstract: case report of isolated metastasis to the spleen in a patient operated due to cancer of the sigmoid colon]. Folia Med Cracov; 2009;50(3-4):71-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Isolated metastatic tumor of the spleen is rare and usually encompass the presence of neoplasmatic dissemination.
  • The most frequent location of metastasis is right lobe of the liver, however solitaire secondary tumor to distant organ such as brain, lung, bone marrow or other might be discovered.
  • Splenectomy is a method of choice therefore may be justified in presence of isolated metastatic disease, because of low complication rate, providing potential long-term survival.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Sigmoid Neoplasms / pathology. Sigmoid Neoplasms / surgery. Splenic Neoplasms / secondary. Splenic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21853873.001).
  • [ISSN] 0015-5616
  • [Journal-full-title] Folia medica Cracoviensia
  • [ISO-abbreviation] Folia Med Cracov
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


92. Tamura M, Dohhba S, Funaki K, Sasaki S, Michiwa Y, Kurosaka Y, Takekawa S, Kiriyama M, Kojima Y, Kita T: [Pulmonary pleomorphic carcinoma; report of 2 cases]. Kyobu Geka; 2006 Jul;59(7):585-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Biopsy of the bone revealed metastatic adenocarcinoma.
  • With a diagnosis of primary lung cancer (cT2N1M1), two-staged operation was performed.
  • Pathological diagnosis was pleomorphic carcinoma [pT2N1M1 (OSS), stage IV].
  • Chest CT revealed a tumor in the right hilar region, which was diagnosed as adenocarcinoma by transbronchial lung biopsy.
  • Only thoracic drainage was performed since metastases to the brain and the rib were demonstrated.
  • Autopsy revealed pleomorphic carcinoma of the lung with metastasis to the brain, costa and mediastinal lymph nodes.
  • [MeSH-major] Adenocarcinoma / radiography. Carcinoma / radiography. Lung Neoplasms / radiography
  • [MeSH-minor] Aged. Aged, 80 and over. Brain Neoplasms / secondary. Female. Humans. Male. Radiography, Thoracic. Spinal Neoplasms / secondary. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16856536.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


93. Klekner A, Varga I, Bognár L, Hutóczki G, Kenyeres A, Tóth J, Hanzély Z, Scholtz B: [Extracellular matrix of cerebral tumors with different invasiveness]. Ideggyogy Sz; 2010 Jan 30;63(1-2):38-43
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Contrarily, brain metastases of anaplastic carcinomas are well-circumscribed intracerebral lesions that can be easily exstirpated in most cases.
  • Four pieces of glioblastoma and four pieces of intracerebral lung adenocarcinoma metastasis from neurosurgical operation were investigated.
  • By immunohistochemistry, neurocan, syndecan, versican and MMP-2 showed alteration in staining intensity according to the mRNA expression, while MMP-9 showed higher staining intensity in the metastatic tumor.
  • [MeSH-major] Adenocarcinoma / chemistry. Biomarkers, Tumor / analysis. Brain Neoplasms / chemistry. Brain Neoplasms / pathology. Extracellular Matrix / chemistry. Extracellular Matrix / pathology. Glioblastoma / chemistry
  • [MeSH-minor] Aged. Brevican. Chondroitin Sulfate Proteoglycans / analysis. Female. Humans. Immunohistochemistry. Lectins, C-Type / analysis. Lung Neoplasms / pathology. Male. Matrix Metalloproteinase 2 / analysis. Matrix Metalloproteinase 9 / analysis. Middle Aged. Neoplasm Invasiveness. Nerve Tissue Proteins / analysis. Neuregulins / analysis. Polymerase Chain Reaction. RNA, Messenger / analysis. Syndecans / analysis. Tenascin / analysis. Versicans / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20420122.001).
  • [ISSN] 0019-1442
  • [Journal-full-title] Ideggyógyászati szemle
  • [ISO-abbreviation] Ideggyogy Sz
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / BCAN protein, human; 0 / Biomarkers, Tumor; 0 / Brevican; 0 / Chondroitin Sulfate Proteoglycans; 0 / Lectins, C-Type; 0 / Nerve Tissue Proteins; 0 / Neuregulins; 0 / RNA, Messenger; 0 / Syndecans; 0 / Tenascin; 0 / neuroglycan C, human; 126968-45-4 / Versicans; 148684-98-4 / NCAN protein, human; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


94. Avraham R, Benish M, Inbar S, Bartal I, Rosenne E, Ben-Eliyahu S: Synergism between immunostimulation and prevention of surgery-induced immune suppression: an approach to reduce post-operative tumor progression. Brain Behav Immun; 2010 Aug;24(6):952-8
Hazardous Substances Data Bank. INDOMETHACIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we tested the hypothesis that integration of peri-operative immunostimulation and blockade of immunosuppression could synergistically improve post-operative anti-metastatic immunity and long-term survival.
  • The second model used the MADB106 mammary adenocarcinoma, assessing its lung tumor retention (LTR) following i.v. inoculation, as well as host marginating-pulmonary NK numbers and activity against this tumor.
  • The blockers prevented this suppression per lung and per single NK cell.

  • MedlinePlus Health Information. consumer health - After Surgery.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NADOLOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • [Cites] J Endocrinol. 1995 Mar;144(3):457-62 [7738470.001]
  • [Cites] Clin Cancer Res. 2009 Apr 15;15(8):2695-702 [19351748.001]
  • [Cites] Lancet. 1995 Dec 9;346(8989):1528-30 [7491049.001]
  • [Cites] Nat Med. 1996 Apr;2(4):457-60 [8597957.001]
  • [Cites] World J Surg. 1996 May;20(4):454-9 [8662134.001]
  • [Cites] Immunol Res. 1998;17(1-2):269-78 [9479588.001]
  • [Cites] J Immunol. 1998 Apr 1;160(7):3251-8 [9531281.001]
  • [Cites] Nat Med. 1998 Jul;4(7):808-13 [9662372.001]
  • [Cites] Surgery. 1998 Sep;124(3):516-25 [9736904.001]
  • [Cites] Br J Surg. 1998 Oct;85(10):1439-42 [9782033.001]
  • [Cites] Ann N Y Acad Sci. 1998 Sep 29;856:22-32 [9917861.001]
  • [Cites] Brain Behav Immun. 2005 Mar;19(2):114-26 [15664784.001]
  • [Cites] Biochem Pharmacol. 2005 Sep 1;70(5):714-24 [15978547.001]
  • [Cites] J Immunol. 2005 Oct 1;175(7):4383-91 [16177079.001]
  • [Cites] Expert Opin Biol Ther. 2005 Sep;5 Suppl 1:S49-59 [16187940.001]
  • [Cites] Cancer Biol Ther. 2005 Sep;4(9):924-33 [16177562.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):369-75 [16428474.001]
  • [Cites] Nat Rev Cancer. 2006 Mar;6(3):240-8 [16498446.001]
  • [Cites] J Mol Med (Berl). 1999 Nov;77(11):769-80 [10619437.001]
  • [Cites] Ann Surg. 2000 Jul;232(1):58-65 [10862196.001]
  • [Cites] Pharmacol Rev. 2000 Dec;52(4):595-638 [11121511.001]
  • [Cites] Nat Immunol. 2001 Apr;2(4):293-9 [11276199.001]
  • [Cites] J Psychosom Res. 2001 May;50(5):277-85 [11399286.001]
  • [Cites] Anesthesiology. 2001 Jun;94(6):1066-73 [11465599.001]
  • [Cites] Cytokine Growth Factor Rev. 2002 Apr;13(2):155-68 [11900991.001]
  • [Cites] Nat Immunol. 2002 Nov;3(11):991-8 [12407406.001]
  • [Cites] Life Sci. 2003 Mar 7;72(16):1825-39 [12586220.001]
  • [Cites] Psychosomatics. 2003 May-Jun;44(3):181-95 [12724499.001]
  • [Cites] J Neuroimmunol. 2003 May;138(1-2):83-91 [12742657.001]
  • [Cites] Ann Surg Oncol. 2003 Oct;10(8):972-92 [14527919.001]
  • [Cites] Immunology. 2004 Mar;111(3):298-305 [15009430.001]
  • [Cites] J Leukoc Biol. 2004 Aug;76(2):322-32 [15123779.001]
  • [Cites] J Immunol. 1983 Aug;131(2):1024-7 [6863925.001]
  • [Cites] J Immunol. 1984 Jan;132(1):534-40 [6197459.001]
  • [Cites] J Immunol. 1985 Apr;134(4):2783-9 [3871818.001]
  • [Cites] Infect Immun. 1985 Jun;48(3):813-7 [2987131.001]
  • [Cites] Cell Immunol. 1986 Apr 15;99(1):108-18 [2944621.001]
  • [Cites] Int J Neurosci. 1988 Feb;38(3-4):455-64 [3286560.001]
  • [Cites] Biochem J. 1990 Dec 1;272(2):327-31 [2176460.001]
  • [Cites] Scand J Immunol. 1993 Jan;37(1):71-6 [8380302.001]
  • [Cites] Eur J Immunol. 1993 Aug;23(8):1826-30 [8102101.001]
  • [Cites] J Exp Med. 1995 Feb 1;181(2):775-9 [7836930.001]
  • [Cites] Nat Med. 2006 Aug;12(8):939-44 [16862152.001]
  • [Cites] Cancer Immunol Immunother. 2006 Nov;55(11):1348-57 [16465528.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):841-52 [17091332.001]
  • [Cites] Brain Behav Immun. 2007 May;21(4):395-408 [17240115.001]
  • [Cites] Clin Cancer Res. 2007 Aug 15;13(16):4677-85 [17699845.001]
  • [Cites] Brain Behav Immun. 2007 Oct;21(7):881-7 [17662574.001]
  • [Cites] Breast Cancer Res Treat. 2008 Jan;107(2):211-23 [17431763.001]
  • [Cites] Ann Surg Oncol. 2008 Jul;15(7):2042-52 [18398660.001]
  • [Cites] Science. 1995 Nov 10;270(5238):908 [7481785.001]
  • (PMID = 20362661.001).
  • [ISSN] 1090-2139
  • [Journal-full-title] Brain, behavior, and immunity
  • [ISO-abbreviation] Brain Behav. Immun.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA125456-03; United States / NCI NIH HHS / CA / R01 CA125456; United States / NCI NIH HHS / CA / R01 CA125456-03
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Adrenergic beta-Antagonists; 0 / Catecholamines; 0 / Cyclooxygenase Inhibitors; 0 / Hormone Antagonists; 0 / Prostaglandin Antagonists; 187348-17-0 / Interleukin-12; 24939-03-5 / Poly I-C; 42200-33-9 / Nadolol; XXE1CET956 / Indomethacin
  • [Other-IDs] NLM/ NIHMS200221; NLM/ PMC2897966
  •  go-up   go-down


95. Yserbyt J, Wilms G, Lievens Y, Nackaerts K: A 63-year-old man with peripheral facial nerve paralysis and a pulmonary lesion. Acta Clin Belg; 2009 May-Jun;64(3):231-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diagnosis of an advanced stage lung adenocarcinoma was finally confirmed by bronchial biopsy.
  • MRI scanning showed diffuse brain metastases and revealed a pontine lesion as the most probable underlying cause of this case of peripheral facial nerve paralysis.
  • RESULTS: According to the MRI findings, the pontine lesion was responsible for the peripheral facial nerve paralysis, as an initial presenting symptom in this case of lung adenocarcinoma.
  • CONCLUSION: This clinical case of a peripheral facial nerve paralysis was caused by a pontine brain metastasis and illustrates a rather rare presenting symptom of metastatic lung cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Brain Neoplasms / diagnosis. Brain Neoplasms / secondary. Facial Paralysis / etiology. Lung Neoplasms / pathology

  • Genetic Alliance. consumer health - paralysis.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19670564.001).
  • [ISSN] 1784-3286
  • [Journal-full-title] Acta clinica Belgica
  • [ISO-abbreviation] Acta Clin Belg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


96. Pentheroudakis G, Golfinopoulos V, Pavlidis N: Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur J Cancer; 2007 Sep;43(14):2026-36
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Published reports on identification of CUP primary site by autopsy or microarray-based multigene expression platforms were retrieved and analysed for year of publication, primary site, patient age, gender, histology, rate of primary identification, manifestations and metastatic deposits, microarray chip technology, training and validation sets, mathematical modelling, classification accuracy and number of classifying genes.
  • RESULTS: From 1944 to 2000, a total of 884 CUP patients (66% males) underwent autopsy in 12 studies after presenting with metastatic or systemic symptoms and succumbing to their disease.
  • A primary was identified in 644 (73%) of them, mostly in the lung (27%), pancreas (24%), hepatobiliary tree (8%), kidneys (8%), bowel, genital system and stomach, as a small focus of adenocarcinoma or poorly differentiated carcinoma.
  • An unpredictable systemic dissemination was evident with high frequency of lung (46%), nodal (35%), bone (17%), brain (16%) and uncommon (18%) deposits.
  • Between the 1944-1980 and the 1980-2000 series, female representation increased, 'undetermined neoplasm' diagnosis became rarer, pancreatic primaries were found less often while colonic ones were identified more frequently.
  • Four studies using microarray technology profiled more than 500 CUP cases using classifier set of genes (ranging from 10 to 495) and reported strikingly dissimilar frequencies of assigned primary sites (lung 11.5%, pancreas 12.5%, bowel 12%, breast 15%, hepatobiliary tree 8%, kidneys 6%, genital system 9%, bladder 5%) in 75-90% of the cases.
  • Discrepant assignment of primary sites by microarrays may be due to the presence of 'sanctuary sites' in autopsies, molecular misclassification and the postulated presence of a pro-metastatic genetic signature.
  • [MeSH-major] Microarray Analysis / methods. Neoplasms, Unknown Primary / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17698346.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


97. Thöm I, Schult-Kronefeld O, Burkholder I, Schuch G, Andritzky B, Kastendieck H, Edler L, Wagener C, Bokemeyer C, Schumacher U, Laack E: Expression of CEACAM-1 in pulmonary adenocarcinomas and their metastases. Anticancer Res; 2009 Jan;29(1):249-54
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In contrast, CEACAM-1 is not expressed in normal lung tissue or melanocytes.
  • It has been demonstrated that an expression in these tissues is associated with the development of metastatic disease.
  • The aim of the present investigation was to analyze a possible association between the expression of CEACAM-1 in pulmonary adenocarcinomas and their lymph node and hematogenous metastatic cells.
  • PATIENTS AND METHODS: CEACAM-1 expression was immunhistochemically evaluated in primary tumors, lymph nodes and distant metastases of 96 patients with metastatic pulmonary adenocarcinoma who had undergone surgery between 1999 and 2002.
  • This investigation demonstrates that its expression is preserved in lymph node and hematogenous metastases, indicating that its expression is of functional significance for both metastatic sites.
  • These results support the prognostic relevance of the expression of CEACAM-1 in pulmonary adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / immunology. Adenocarcinoma / secondary. Antigens, CD / biosynthesis. Cell Adhesion Molecules / biosynthesis. Lung Neoplasms / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Brain Neoplasms / immunology. Brain Neoplasms / secondary. Female. Humans. Male. Middle Aged. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19331157.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD66 antigens; 0 / Cell Adhesion Molecules
  •  go-up   go-down


98. Beachkofsky TM, Wisco OJ, Osswald SS, Osswald MB, Hodson DS: Pulmonary cutaneous metastasis: a case report and review of common cutaneous metastases. Cutis; 2009 Dec;84(6):315-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The literature on cutaneous metastatic disease can be difficult to interpret because of inconsistent study design and analysis among authors.
  • Diagnosis of cutaneous metastatic disease carries a grave prognosis.
  • The most common cutaneous metastasizing carcinomas--breast, lung, and colorectal cancer--also are discussed.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology. Skin Neoplasms / secondary
  • [MeSH-minor] Brain Neoplasms / secondary. Fatal Outcome. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20166573.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  •  go-up   go-down


99. Basso U, Brunello A, Magro C, Favaretto A, Monfardini S: Overprotective caregivers of elderly cancer patients: a case report. Tumori; 2006 Jul-Aug;92(4):362-3
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This case report concerns a woman with metastatic lung carcinoma who was sincerely informed and successfully treated with chemotherapy and gefitinib only after gaining the trust of her overprotective daughter.
  • [MeSH-major] Adenocarcinoma. Brain Neoplasms / secondary. Breast Neoplasms / pathology. Caregivers. Lung Neoplasms. Negotiating. Neoplasms, Second Primary

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Caregivers.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17036533.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


100. Kaplan-Lefko PJ, Sutherland BW, Evangelou AI, Hadsell DL, Barrios RJ, Foster BA, Demayo F, Greenberg NM: Enforced epithelial expression of IGF-1 causes hyperplastic prostate growth while negative selection is requisite for spontaneous metastogenesis. Oncogene; 2008 May 1;27(20):2868-76
SciCrunch. Marmoset Gene list: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Expression of IGF-1(des) was sufficient to cause hyperplastic lesions in all mice, however the well-differentiated lesions did not progress to adenocarcinoma within a year.
  • Remarkably, crossing the PB-Des mice to an established model of prostate cancer delayed progression of organ-confined tumors and emergence of metastatic lesions in young mice.
  • While dissemination of metastatic lesions was widespread in old bigenic mice we did not detect IGF-1(des) in poorly differentiated primary tumors or metastatic lesions.
  • [MeSH-minor] Adenocarcinoma / secondary. Animals. Brain Neoplasms / secondary. Cell Differentiation / physiology. Epithelium / metabolism. Epithelium / pathology. Heart Neoplasms / secondary. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Male. Mice. Mice, Transgenic. Splenic Neoplasms / secondary. Thymus Neoplasms / secondary. Urologic Neoplasms / secondary






Advertisement